Autonomic nerve stimulation for orthostatic tachycardia syndrome
By sensing changes in body position and delivering ANS therapy, particularly parasympathetic nerve stimulation, the prevention and relief of POTS symptoms were addressed, and effective regulation of heart rate was achieved.
Patent Information
- Application Number
- CN202580025296.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-05
- Filing Date
- 2025-03-18
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies are insufficient to effectively prevent or alleviate postural orthostatic tachycardia syndrome (POTS) and its related symptoms, especially the rapid increase in heart rate during changes in body position.
By sensing acceleration and cardiac signals, changes in body position are detected and autonomic nerve stimulation (ANS) therapy is delivered, especially electrical stimulation that increases parasympathetic tone, to reduce heart rate.
It effectively reduces or prevents POTS symptoms by increasing parasympathetic tone to slow the heart rate and alleviate the rapid increase in heart rate caused by changes in body position.
Smart Images

Figure CN123125015A_ABST
Abstract
Description
[0001] This application claims the benefit of U.S. Provisional Patent Application Serial No. 63 / 575,605, filed April 5, 2024, the entire contents of which are incorporated herein by reference. Technical Field
[0002] This disclosure relates in its entirety to medical devices and methods for delivering electrical stimulation to alter parasympathetic tone. Background Technology
[0003] Medical devices can sense electrophysiological signals from the heart, brain, nerves, muscles, or other tissues. These devices can be implantable, wearable, or external, using implantable and / or surface (skin) electrodes to sense these electrophysiological signals. In some cases, such devices can be configured to deliver therapy based on the sensed electrophysiological signals. For example, implantable or external pacemakers, cardiopulmonary bypass devices, and cardiac monitors sense electrical signals from a patient's heart. Medical devices can sense electrical signals from the heart and use electrodes to deliver electrical stimulation to the heart for therapeutic purposes such as cardiac pacing pulses and / or cardiopulmonary bypass (CV / DF) shocks. These electrodes may be carried by medical leads extending from the medical device to position the electrodes within or near the patient's heart.
[0004] A pacemaker or cardioverter defibrillator delivers therapeutic electrical stimulation to the heart via electrodes carried by one or more medical electrical leads coupled to the medical device. Cardiac signals sensed from the heart can be analyzed to detect abnormal rhythms. Upon detection of an abnormal rhythm such as bradycardia, tachycardia, or fibrillation, one or more appropriate electrical stimulation pulses can be delivered to restore or maintain a more normal heart rhythm. For example, an implantable cardioverter defibrillator (ICD) can deliver bradycardia pacing pulses to a patient's heart without sensing intrinsic myocardial depolarization signals (e.g., R waves), deliver antitachycardia pacing pulses in response to the detection of tachycardia, or deliver a CV / DF shock to the heart upon the detection of tachycardia or fibrillation.
[0005] In patients with intact atrioventricular (AV) conduction, atrial depolarization during atrial tachyarrhythmias can conduct rapidly and / or irregularly to the ventricles, which can be symptomatic. Patients (some of whom have otherwise normal heart rhythms) may experience postural orthostatic tachycardia syndrome (POTS) when atrial tachycardia is triggered in response to a change in body position (e.g., standing up). Symptoms of POTS can include dizziness, syncope, chest pain, and shortness of breath. POTS can severely disrupt daily life and may or may not resolve spontaneously. Summary of the Invention
[0006] Generally, this disclosure relates to medical devices and techniques for controlling and delivering autonomic nerve stimulation (ANS) therapy to prevent or reduce the likelihood of POTS or POTS-related symptoms. The medical device may be configured to sense cardiac electrical signals, patient position, and patient body activity. In response to detecting an acceleration signal indicating patient body movement during a change in position, the medical device may deliver ANS therapy to reduce the likelihood of the patient experiencing POTS or at least alleviate POTS symptoms. In some examples, the medical device may determine that the change in position is accompanied by a patient activity level below a threshold level, and that the heart rate increases at least at the threshold change and / or increases to a rate greater than the threshold rate.
[0007] In one example, this disclosure provides a medical device system including: a sensor circuit configured to sense an acceleration signal; a cardiac signal sensing circuit configured to sense cardiac signals; and a memory configured to store postural change movement criteria. The medical device system also includes control circuitry configured to: detect signal spikes from the acceleration signal that satisfy the postural change movement criteria; detect a first heart rate from the cardiac signals sensed by the cardiac signal sensing circuit after the detection of the signal spike; and detect an increased heart rate based on the first heart rate. The medical device system further includes a treatment delivery circuitry configured to deliver autonomic nerve stimulation (ANS) to reduce the first heart rate in response to the control circuitry detecting the spike and the increased heart rate.
[0008] In another example, this disclosure provides a method comprising: sensing an acceleration signal; sensing a cardiac signal; storing a postural change movement criterion in a medical device memory; and detecting a signal spike from the acceleration signal that satisfies the postural change movement criterion. The method further comprises: detecting a first heart rate from the cardiac signal sensed after detecting the signal spike; detecting an increased heart rate based on the first heart rate; and delivering an ANS to reduce the first heart rate in response to detecting the spike and the increased heart rate.
[0009] In another example, this disclosure provides a non-transitory computer-readable medium storing a postural change exercise criterion and a set of instructions, which, when executed by control circuitry of a medical device system, cause the medical device system to: sense an acceleration signal; sense a cardiac signal and store it in the medical device memory; detect a signal spike from the acceleration signal that satisfies the postural change exercise criterion; detect a first heart rate from the cardiac signal sensed after the detection of the signal spike; and detect an increased heart rate based on the first heart rate. The instructions further cause the medical device system, in response to detecting the spike and the increased heart rate, to deliver an ANS to reduce the first heart rate.
[0010] The present invention is intended to provide an overview of the subject matter described herein. It is not intended to provide an exclusive or exhaustive interpretation of the devices and methods described in detail in the following drawings and description. Further details of one or more examples are set forth in the following drawings and description. Attached Figure Description
[0011] Figure 1 These are conceptual diagrams of medical device systems configured to sense patient signals and deliver ANS treatment, based on some examples.
[0012] Figure 2 This is a conceptual diagram of an IMD based on some examples for sensing patient signals and delivering ANS.
[0013] Figure 3 This is a conceptual diagram illustrating a medical device system that can be configured to sense patient signals and deliver ANS treatment, according to yet another example.
[0014] Figure 4 This is a conceptual diagram of an IMD configured to sense cardiac signals, sense acceleration signals, and deliver an ANS, based on some examples.
[0015] Figure 5 This is a flowchart of a method for controlling ANS treatment by a medical device system, based on some examples.
[0016] Figure 6 This is a flowchart of a method for controlling ANS treatment by a medical device system, based on another example.
[0017] Figure 7 This is a diagram illustrating an example accelerometer axis signal that can be sensed by the sensor circuitry of an IMD configured to deliver ANS treatment.
[0018] Figure 8 This is a diagram showing the ANS treatment trigger conditions and ANS delivery timeline based on some examples.
[0019] Figure 9 This is a diagram illustrating the ANS triggering conditions and the timeline of ANS delivery based on another example.
[0020] Figure 10 This is a diagram showing different gradual decrease rates that can be applied to ANS delivery control parameters to gradually terminate ANS treatment in response to the detection of ANS termination conditions.
[0021] Figure 11 This is a timing diagram of an ANS pulse train that can be delivered by an IMD, based on some examples.
[0022] Figure 12This is a flowchart of a method for controlling ANS treatment performed by a medical device system, based on another example. Detailed Implementation
[0023] Generally, this disclosure describes a medical device and technique for delivering ANS. The ANS delivered by the medical device disclosed herein is electrical stimulation delivered to areas of the autonomic nervous system to increase parasympathetic tone. Activation of the parasympathetic nervous system, or an increase in parasympathetic tone, functions to put the body into a resting or relaxed state and is associated with slowed heart rate, slowed respiratory rate, and decreased blood pressure. Activation of the sympathetic nervous system, or an increase in sympathetic tone, functions to put the body into an alert state and is associated with increased heart rate, increased respiratory rate, and increased blood pressure. The sympathetic nervous system is triggered by stress and is associated with the "fight or flight" response. By increasing parasympathetic tone, the rapid heart rate during a POTS attack can be slowed to reduce or prevent symptoms associated with POTS.
[0024] An ANS used to increase parasympathetic tone to reduce heart rate can be delivered to the right or left vagus nerve or its branches that innervate the SA node, atrial myocardium, and / or AV node. The ANS can be delivered at an epicardial site, an endocardial site, at the SA node, AV node fat pad, or within the myocardium (e.g., via an electrode advanced into the myocardium from the epicardium or endocardium), as an example, or at any other operational site that induces an increase in parasympathetic tone and a decrease in heart rate, which may be a decrease in atrial and / or ventricular rate.
[0025] Figure 1 This is a conceptual diagram of a medical device system 10, which includes an implantable medical device (IMD) 14 coupled to transvenous leads 16 and 18. The IMD 14 can be configured to deliver electrical stimulation pulses and sense cardiac electrical signals in the right atrium (RA), right ventricle (RV), and / or left ventricle (LV). An IMD housing 15 encapsulates the device in conjunction with the following description. Figure 4 The internal circuitry of the various circuits and components described corresponds to the functionality of IMD 14 as disclosed herein, including the delivery of ANS.
[0026] The IMD housing 15 may form a hermetically sealed enclosure that protects the internal components of the IMD 14. The housing 15 may be formed of a conductive material such as titanium or a titanium alloy. The housing 15 may function as an electrode (sometimes referred to as a "can" electrode). The housing 15 may be used as an active can electrode for delivering high-voltage CV / DF electrical shock pulses to the heart 8 to terminate rapid arrhythmias (e.g., ventricular tachycardia or fibrillation). In other examples, the housing 15 may be used to deliver unipolar, relatively low-voltage cardiac pacing pulses and / or for sensing cardiac electrical signals in conjunction with electrodes carried by leads coupled to the IMD 14. In other cases, the housing 15 of the IMD 14 may include multiple electrodes located on an external portion of the housing. The external portion of the housing 15 serving as electrodes may be coated with a material such as titanium nitride, for example, to reduce post-stimulation polarization artifacts.
[0027] IMD 14 includes a connector assembly (or “connector block”) 17, which includes an insulated electrical feedthrough through a housing 15 to allow for the conduction of conductors (which extend within leads 16 and 18) Figure 1 (Not shown) provides an electrical connection between the antenna (and the electronic components enclosed in the housing 15). Figure 1 (Not shown) may be carried in connector assembly 17 for coupling RF signals transmitted to / from external device 50 to telemetry circuitry encapsulated by housing 15. As described below, housing 15 may encapsulate one or more processing circuits, memory, transceiver, cardiac electrical signal sensing circuitry, therapeutic delivery circuitry, power supply, and other components for sensing cardiac electrical signals, processing and analyzing the sensed cardiac electrical signals, and delivering electrical stimulation pulses to the patient's heart 8 as needed.
[0028] In the example shown, connector assembly 17 is configured to receive proximal lead connectors 40 and 42 for each of the RA lead 16 and RV lead 18, respectively. Each lead 16 and 18 can be advanced via a vein for positioning electrodes for sensing and stimulation in the atrium or ventricle of the heart 8. The proximal portions of each lead 16 and 18 can be configured as industry-standard or custom lead connectors 40 and 42, respectively. Connector assembly 17 includes connector holes appropriately sized to receive the proximal portions of each lead 16 and 18 (e.g., lead connectors 40 and 42). Each connector hole includes electrical contacts that align and physically engage with corresponding electrical contacts of the respective lead connector 40 or 42, thereby providing physical and electrical connection between leads 16 and 18 and IMD 14.
[0029] In the example shown, the RA lead 16 includes an elongated lead body 41, a proximal lead connector 40, and distal electrodes 20 and 22. The RA lead 16 is equipped with pacing electrodes 20 and sensing electrodes 22, shown as a distal electrode 20 and a ring electrode 22 spaced proximally from the distal electrode 20 along the RA lead body 41. Electrodes 20 and 22 are each connected to a corresponding insulating conductor extending within the elongated body 41. Each insulating conductor is coupled at its proximal end to an electrical connector of the proximal lead connector 40, which is electrically connected to internal IMD circuitry via various electrical feedthroughs in the IMD connector assembly 17. The distal electrode 20 can be used as a cathode electrode, while the ring electrode 22 serves as an anode electrode for delivering bipolar electrical stimulation pulses.
[0030] The RA lead 16 can be advanced via a vein to position the distal ends of its carrier electrodes 20 and 22 into the RA for delivery of anastomotic nerve impulses (ANS), sensing atrial signals, and delivering atrial pacing pulses. The distal electrode 20 can be positioned along the lower portion of the superior vena cava for delivery of ANS in the region of the superior right atrial ganglion plexus or SA node. The distal electrode 20 can be implanted in the region of the cardiac plexus (e.g., along the posterior wall of the RA, adjacent to the coronary sinus ostium 9). In other examples, the distal portions of the carrier distal electrode 20 and the loop electrode 22 of the RA lead 16 can be advanced in the right brachiocephalic vein for delivery of ANS to the vagus plexus. In some examples, the distal electrode 20 can be positioned along the lower portion of the posterior RA endocardial wall, adjacent to the coronary sinus ostium 9, to provide ANS for increasing parasympathetic tone according to the techniques described herein.
[0031] In addition to delivering ANS, the terminal electrode 20 and the loop electrode 22 can also be used to deliver bipolar atrial pacing pulses for pacing RA by capturing atrial myocardial tissue. In some examples, unipolar atrial pacing pulses may be delivered by one of the electrodes 20 or 22 and the IMD housing 15. In other examples, the RA lead 16 may include more than two electrodes to provide two or more pairs of electrodes positioned along the RA lead body 43 to facilitate delivery of ANS at a desired ANS delivery site, delivery of atrial pacing at a desired pacing site that may be the same as or different from the ANS delivery site, and sensing of atrial signals.
[0032] The RV lead 18 includes: an elongated lead body 43 having a proximal connector 42 at its proximal end for coupling the lead 18 to the IMD connector assembly 17; and electrodes 24, 26, 28, and 30 carried along a distal portion of the lead body 43. The RV lead 18 can be advanced via a vein through the RA and into the RV to position the electrodes 24, 28, and 30 within the RV. The RV lead 18 is shown carrying a distal terminal electrode 28 and a ring electrode 30 proximal to the terminal electrode 28 for bipolar sensing of cardiac electrical signals in the RV and delivery of ventricular pacing pulses. The terminal electrode 28 can serve as a cathode electrode for pacing and sensing, while the ring electrode 30 serves as an anode electrode for delivering bipolar ventricular pacing pulses. In other examples, the terminal electrode 28 can be paired with one of the coil electrodes in the IMD housing 15 or coil electrodes 24 or 26 for delivering ventricular pacing pulses.
[0033] The RV lead terminal electrode 28 is shown implanted in the apex of the RV for delivering ventricular myocardial pacing. However, it should be understood that the RV lead electrode location is illustrative in nature and not limiting. For example, the RV lead terminal electrode 28 may be implanted in the ventricular septum for delivering septal pacing, which may include delivering ventricular pacing to the lower portion of the His bundle, or implanted in the region of the left and / or right bundle branches to deliver ventricular pacing pulses via at least a portion of the heart's natural conduction system.
[0034] RV lead 18 is shown carrying an RV coil electrode 24 spaced proximally from the annular electrode 30 and a superior vena cava (SVC) coil electrode 26 spaced proximally from the RV coil electrode 24. The SVC coil electrode 26 may be carried along the length of the RV lead body 43 such that, as the distal end of the RV lead 18 is advanced within the RV, the SVC coil electrode is at least partially positioned within the RA and / or SVC. Coil electrodes 24 and 26 are elongated electrodes with a relatively high surface area compared to electrodes 20, 22, 28, and 30. For example, the surface area of coil electrodes 24 and 26 may be 50 to 100 times larger than that of electrodes 20, 22, 28, and 30. For convenience, electrodes 24 and 26 are referred to herein as “coil electrodes” because they may take the form of coiled electrodes, which may comprise a single wire or filament or multiple wires or filaments (e.g., braided multifilaments, stranded multifilaments, etc.) spirally wound around the longitudinal portion of lead body 43 to provide an electrode with a relatively high surface area for delivering high-voltage CV / DF shocks. Electrodes 24 and 26 may be configured as other types of high-surface-area electrodes that can be used to deliver CV / DF shocks, including strip electrodes, plate electrodes, serpentine electrodes, zigzag electrodes, segmented electrodes, or other types of physical electrode configurations that provide a relatively large surface area and low impedance, which do not necessarily include coiled wire. In other examples, IMD 14 may not be configured to deliver high-voltage CV / DF shocks, in which case coil electrodes 24 and 26 are optional and may not be included on RV lead 18.
[0035] Each of the electrodes 24, 26, 28, and 30, carried by the RV lead body 43, is connected to a corresponding insulated conductor extending within the body 43 of the RV lead 18. In some examples, the lead body 43 may be a multi-cavity lead body to accommodate multiple insulated conductors. The proximal end of the insulated conductor is coupled to a corresponding electrical connector of the proximal lead connector 42. Figure 1 (not shown in the image) for providing an electrical connection to the IMD 14 via an electrical feeder in connector assembly 17.
[0036] The RV lead terminal electrode 28 and the RA lead terminal electrode 20 can be active fixation electrodes, providing not only cardiac electrical signal sensing and cardiac pacing functionality, but also fixation of the distal ends of leads 18 and 16 at the implantation site, respectively. Figure 1In this embodiment, the RA terminal electrode 20 (which can be used to deliver atrial pacing and ANS) and the RV terminal electrode 28 (for delivering ventricular pacing) are each shown as screw-in electrodes capable of rotatably advancing into cardiac tissue to provide lead fixation. In other examples, terminal electrodes 20 and / or 28 may be configured as fishhook electrodes, hemispherical electrodes, button electrodes, or other types of electrodes. When the terminal electrodes 20 or 28 of the medical leads 16 or 18 do not provide fixation to the distal end of the elongated lead body, the corresponding RA lead 16 or RV lead 18 may be equipped with other fixation mechanisms (such as fangs or hooks) that engage with cardiac tissue at the implantation site to facilitate stable fixation of the terminal electrodes 20 and 28 at the desired treatment delivery site.
[0037] The proximal annular electrode 22 of the RA lead 16 and the proximal annular electrode 30 of the RV lead 18 can each be an annular electrode wholly or partially external to the corresponding lead body 41 or 43. In various examples, the relatively low surface area pacing / sensing electrodes 20, 22, 28, and 30 can be implemented as annular electrodes, short coil electrodes, button electrodes, hemispherical electrodes, directional electrodes, segmented electrodes, spiral electrodes, fishhook electrodes, or other shaped electrodes, and are not limited to only the annular electrodes and spiral screw-in electrodes shown herein.
[0038] RA lead electrodes 20 and 22 and RV lead electrodes 28 and 30 are relatively small surface area electrodes that can be used to sense cardiac electrical signals and to deliver relatively low-voltage cardiac pacing pulses, ANS, anti-tachycardia pacing (ATP) therapy, or other therapeutic cardiac pacing pulses. Electrodes 20, 22, 28, and 30 are sometimes referred to as “pacing electrodes / sensing electrodes” because they are typically configured for use in low-voltage applications, for example, as cathodes or anodes for delivering pacing pulses and / or sensing cardiac electrical signals, in contrast to delivering high-voltage CV / DF shocks.
[0039] Electrodes 20, 22, 24, 26, 28, and 30 may be formed of titanium, platinum, iridium, or alloys thereof (by way of example and not limitation) and may include low-polarity coatings such as titanium nitride, iridium oxide, ruthenium oxide, platinum black, etc. Lead bodies 41 and 43 may each be formed of a non-conductive material, including silicone, polyurethane, fluoropolymers, mixtures thereof, and / or other suitable materials. Each lead body may be shaped to form one or more cavities within which one or more insulated electrical conductors extend between the electrical connectors of proximal lead connectors 40 and 42 and the corresponding electrodes carried by the lead body. Lead bodies 41 and 43 may be generally tubular or cylindrical in shape, but in some examples may have a flat or strip shape. Lead bodies 41 and 43 may have pre-formed shapes (such as curves or bends) that may follow the distal portion of the lead body to facilitate guidance and implantation of the distal end of the lead body at the target implantation site. In other examples, lead bodies 41 and 43 may be elongated, flexible bodies without any pre-formed shape or curve.
[0040] It should be understood that although the IMD 14 is described as a dual-chamber device capable of sensing and delivering electrical stimulation therapy in both the RA and RV, in other examples, the IMD 14 may be, for example, a multi-chamber device coupled to a third lead that may be advanced in the coronary sinus ostium 9 into the cardiac vein for sensing and pacing the left ventricle (LV). In still other examples, the IMD 14 may be coupled only to the RA lead 16. However, in medical device systems configured to deliver ANS, ventricular pacing capability may be desirable to avoid ventricular bradycardia during ANS and / or to provide frequency-responsive pacing in the event of increased patient activity during ANS.
[0041] exist Figure 1 In this embodiment, external device 50 is shown communicating telemetry with IMD 14 via wireless communication link 51. External device 50 may be embodied as a programmer used in a hospital, clinic, or physician's office to retrieve data from IMD 14 and program the operating parameters and algorithms within IMD 14 to control IMD functions. Alternatively, external device 50 may be embodied as a home monitor or handheld device for retrieving data from IMD 14. External device 50 can be used to program cardiac signal sensing parameters, cardiac rhythm detection parameters, treatment delivery control parameters (including ANS control parameters, and other operating and control parameters) used by IMD 14.
[0042] External device 50 may include processor 52, memory 53, display unit 54, user interface 56, and telemetry unit 58. Processor 52 executes instructions stored in memory 53. Processor 52 may include any one or more of the following: microprocessor, controller, digital signal processor (DSP), application-specific integrated circuit (ASIC), field-programmable gate array (FPGA), or equivalent discrete or analog logic circuitry. In some examples, processor 52 may include multiple components (such as any combination of one or more microprocessors, one or more controllers, one or more DSPs, one or more ASICs, or one or more FPGAs) and other discrete or integrated logic circuitry. The functionality of processor 52 as defined herein may be embodied in software, firmware, hardware, or any combination thereof.
[0043] The memory 53 may comprise any volatile, non-volatile, magnetic, optical, or electrical medium, such as random access memory (RAM), read-only memory (ROM), non-volatile RAM (NVRAM), electrically erasable programmable ROM (EEPROM), flash memory, or any other digital or analog medium. The memory 53 may be configured to store instructions executed by the processor 52 to acquire data received from the IMD 14 and generate a GUI on the display unit 54, according to the techniques disclosed herein. The memory 53 may store various operating parameter settings for the IMD 14, which can be used by the processor 52 to generate various GUI windows, menus, reports, etc.
[0044] Display unit 54 can generate and display cardiac electrical signals, programming operation settings for IMD 14 and other devices, and patient-related data received from processor 52 (which can be received from IMD 14 via telemetry unit 58). Display unit 54 can be configured to generate a GUI including various windows, icons, user-selectable menus, etc., to facilitate user interaction with external device 50, such as for programming ANS control parameters described herein. Display unit 54 can be used as an input and / or output device using technologies including liquid crystal displays (LCDs), quantum dot displays, dot matrix displays, light-emitting diode (LED) displays, organic light-emitting diode (OLED) displays, cathode ray tube displays, electronic ink, or monochrome, color, or any other type of display capable of generating tactile, audio, and / or visual outputs. In some examples, display unit 54 is a presence-sensitive display that can be used as a user interface device, operating as one or more input devices and one or more output devices.
[0045] User interface unit 56 may include a mouse, touchscreen, keypad, etc., to enable users to interact with external device 50, for example, to initiate and terminate query sessions to retrieve data from IMD 14, adjust settings of display unit 54, type programming commands or make selections, or make other user requests. Telemetry unit 58 includes a transceiver and antenna configured for bidirectional communication with telemetry circuitry included in IMD 14, for example, in response to user requests.
[0046] Telemetry unit 58 is configured to operate in conjunction with processor 52 to transmit and receive data related to IMD functionality via wireless communication link 51 with IMD 14. Communication link 51 may use technologies such as Bluetooth. ® The communication link 51 can be established using a radio frequency (RF) link with bandwidths such as Wi-Fi, Medical Implantable Communication Service (MICS), or other communication bands. In some examples, external device 50 may include a programming head placed close to IMD 14 to establish and maintain the communication link 51, and in other examples, external device 50 and IMD 14 may be configured to communicate using a distance telemetry algorithm and circuitry that does not require the programming head and does not require user intervention to maintain the communication link.
[0047] It is conceivable that the external device 50 can be connected to a communication network, either wired or wirelessly, via telemetry circuitry 58 including a transceiver and antenna, or via hardwired communication lines for transmitting data to a centralized database or computer, to allow for remote patient management. An example of a remote patient management system is CARELINK. ® The network (Medtronic, Inc., Minneapolis, MN). Review of operating parameter settings and other data collected from the IMD 14 can be performed remotely by a clinician who, for example, authorizes programming of the operating parameters in the IMD 14 after reviewing reports and cardiac electrical signals, as well as other device-related data such as labeled channel data, treatment delivery history, warnings generated by the IMD, etc.
[0048] In some examples, external device 50 may be a handheld device or a home monitor that can be used by the patient or caregiver to input a POTS confirmation signal via user interface 56 when the patient experiences a POTS episode (e.g., during or after experiencing POTS symptoms). The POTS confirmation signal may be sent to IMD 14. In some cases, IMD 14 may respond to the POTS confirmation signal by triggering the delivery of ANS treatment. In some examples, receiving the POTS confirmation signal from external device 50 may cause IMD 14 to deliver ANS if at least one other ANS triggering condition is met, as further described below.
[0049] The history of POTS attacks and delivered ANS treatments can be recorded in the memory of IMD 14 and / or the memory of external device 50. The history of POTS attacks (which can be confirmed by signals entered by the user) and associated patient activity data, heart rate data, and / or postural change data allow clinicians to customize the ANS control parameters programmed in IMD 14 according to patient needs. For example, as further described below, IMD 14 may include an accelerometer for sensing acceleration signals to detect changes in patient body position and for determining activity metrics related to the patient's activity level. IMD 14 can detect triggering conditions for initiating ANS treatment from the acceleration signals and from cardiac signals sensed by IMD 14. Various thresholds or other parameters used by IMD 14 to detect ANS treatment triggering conditions can be programmed into IMD 14 using external device 50 or another device programmer; in some examples, this may be based on the history of POTS attacks and delivered ANS treatments. The ANS delivery control parameters can be programmed using an external device 50 or another programming device, and can be adjusted when the patient or other caregivers confirm an attack of POTS if the ANS is not effective in reducing or preventing POTS symptoms.
[0050] Figure 2 This is a conceptual diagram of an IMD 114 for sensing cardiac signals and delivering anastomotic pressure (ANS) based on some examples. In this example, the leadless IMD 114 is implanted in the RA for delivering ANS and ventricular pacing from an atrial location. The IMD 114 can be a transcatheter device that can be delivered to the RA via a catheter or other delivery device for complete implantation within the RA. In some examples, the IMD 114 can be positioned to deliver ventricular pacing pulses from a right atrial approach via the heart's natural conduction system and / or ventricular myocardium. The distal end 102 of the IMD 114 can be positioned below the atrial septum, below the AV node, and near the tricuspid annulus to position the terminal electrode 128 for advancement toward the His bundle of the natural His-Purkinje conduction system into the atrial septum. A ring electrode 130 spaced proximally relative to the terminal electrode 128 can be used together with the cathode terminal electrode 128 as a return electrode to pace the right and left ventricles via the His-Purkinje system and / or ventricular myocardium. The terminal electrode 128 can be positioned to capture at least a portion of the His bundle and / or ventricular myocardium to deliver ventricular pacing from the atrial implantation site of the IMD 114.
[0051] In some examples, the IMD 114 may be capable of both dual-chamber sensing and pacing. For example, a distal loop electrode 120 may be included on the pacemaker housing 115 and may be used in conjunction with a proximal loop electrode 130 for sensing atrial P waves and, in some examples, delivering atrial pacing pulses. In some examples, the distal loop electrode 120 may be referred to as an "atrial electrode" because it can be used for atrial sensing and pacing when the IMD 114 is implanted in the atrium. However, in some examples, the distal loop electrode 120 may be additionally or alternatively used for delivering ANS. In other examples, one or more electrodes may be provided on or extending from the distal end 102 of the IMD 114 for delivering ANS according to the techniques disclosed herein. Examples of various pacing electrode arrangements and medical device configurations for providing ventricular pacing along the heart’s natural conduction system, which can be combined with the ANS technology disclosed herein, are disclosed in whole in U.S. Publication No. 2021 / 0228892 (Kornet et al., filed January 25, 2021), U.S. Patent No. 11,426,578 (Yang et al., filed September 13, 2018), and U.S. Patent No. 11,007,369 (Sheldon et al., filed November 8, 2018), the entire contents of which are incorporated herein by reference.
[0052] exist Figure 2 In one example, the cathode terminal electrode 128 is shown as a screw-in helical electrode that provides fixation at the implantation site to the IMD 114 and acts as a pacing and sensing electrode. In other examples, the terminal electrode 128 may be other types of electrodes that may or may not provide fixation of the IMD 114 at the implantation site. Other fixation components, such as fangs, hooks, barbs, etc., may be provided along the distal end 102 for providing fixation of the IMD 114 at the implantation site, enabling ANS treatment delivery and delivery of ventricular pacing. The IMD 114 may include one or more ring electrodes (e.g., ring electrodes 120 and 130) of an outer housing 115. In other examples, the IMD 114 may include other types of electrodes, such as hook electrodes, button electrodes, hemispherical electrodes, segmented electrodes, or other types of electrodes arranged along the housing 115 for at least providing cardiac electrical signal sensing, ventricular pacing, and ANS.
[0053] Figure 3 This is a conceptual diagram illustrating an IMD system 110, according to another example, for sensing cardiac electrical signals, delivering an atrial pacing (ANS), and delivering ventricular pacing. The IMD system 110 is a multi-device system comprising an IMD 114' implanted in the atrial respirator (RA) and an IMD 116 implanted in the ventricular respirator (RV). IMD 114' provides atrial signal sensing, atrial pacing, and an ANS. IMD 116 provides ventricular signal sensing and ventricular pacing.
[0054] In some examples, IMD 114' and IMD 116 are transcatheter leadless pacemakers that can be fully implanted within the heart chamber. The size of IMD 114' and IMD 116 can be reduced compared to subcutaneously implanted pacemakers, and their shape can be generally cylindrical to enable transvenous implantation via a delivery catheter.
[0055] The IMD 114' can be implanted entirely within the right atrium (RA) and can be implanted along the posterior wall of the RA (adjacent to the coronary sinus 9, operatively close to the cardiac nerve plexus and AV node) for delivery of antrial nerve impulses (ANS). The IMD 114' may include a distal terminal electrode 120' for delivery of atrial pacing pulses, delivery of ANS, and sensing of atrial electrical signals. The IMD 114' may include at least one proximal electrode 122, which may be a ring electrode attached to an outer shell 115 to be coupled with electrode 120' for sensing and therapeutic delivery electrode vectors for delivery of atrial pacing pulses, ANS, and sensing of atrial electrical signals. In some examples, the IMD 114' may be implanted at an epicardial location outside the heart 8, for example, where the distal terminal electrode 120' is implanted in an operative location within the posterior RA and / or the atrial septum for delivery of ANS therapy, for example, targeting vagal branches that innervate the SA or AV node.
[0056] The IMD 116 can be implanted entirely within the right ventricle (RV) as shown, or implanted on the ventricular chamber, for example, at an epicardial location. The ventricular pacemaker 116 can be positioned along the ventricular septum as shown to deliver ventricular pacing pulses to a region of the natural conduction system, such as the right bundle branch, left bundle branch, or the lower portion of the His bundle. Other operating locations for the IMD 116 are possible, such as near the apex of the RV.
[0057] The IMD 116 may include a distal terminal electrode 128 and a proximal annular electrode 130 mounted on a housing of the IMD 116 for sensing ventricular electrical signals and delivering ventricular pacing pulses. It should be noted that the ventricular pacing and sensing electrode pairs 128 and 130 were previously... Figure 2 The image is shown as being carried by an IMD 114, which is positioned to sense ventricular electrical signals and deliver ventricular pacing pulses from the RA location via ventricular sensing and pacing electrodes 128 and 130. The ventricular pacing pulses can be delivered by electrodes 128 and 130 to capture ventricular myocardium, a portion of the natural conduction system, or both.
[0058] As generally described herein, the IMD system 110 may include cardiac electrical signal sensing circuitry. For example, IMD 114' may include atrial electrical signal sensing circuitry configured to sense atrial P waves (via electrodes 120' and 122) accompanied by depolarization of the atrial myocardium. IMD 116 may include ventricular electrical signal sensing circuitry configured to sense ventricular R waves (via electrodes 128 and 130) accompanied by depolarization of the ventricular myocardium.
[0059] IMD system 110 may also include therapeutic delivery circuitry configured to deliver an atrial pacing pulse and an atrial pacing pulse. For example, IMD 114' may include therapeutic delivery circuitry configured to generate and deliver atrial pacing pulses via electrodes 120' and 122 in the absence of a sensed intrinsic atrial P wave. The therapeutic delivery circuitry of IMD 114' may also be configured to generate an atrial pacing pulse to suppress the atrial rate and avoid or mitigate POTS. IMD 116 may include therapeutic delivery circuitry configured to deliver a ventricular pacing pulse in the absence of a sensed intrinsic ventricular R wave.
[0060] IMD 114' and / or IMD 116 may include one or more fixation members, such as fixation teeth, fixation spirals, or other fixation members for engagement with cardiac tissue at the respective implantation site. In the example shown, IMD 114' is provided with a distal terminal electrode 120' in the form of a button electrode or a hemispherical electrode. IMD 114' may have a fixation member 113 including one or more teeth configured to engage with cardiac tissue at the implantation site. In the example shown, IMD 116 is provided with a distal terminal electrode 128, which is a spiral electrode that provides fixation of IMD 116 at the implantation site. It should be appreciated that IMD 114' and IMD 116 may be provided with, in addition to Figure 3 Other types of electrodes and / or fixtures besides those shown in the examples, such as any of the example electrodes or fixtures listed herein.
[0061] The IMDs 114' and 116 of the medical device system 110 may be able to communicate with the external device 50 ( Figure 1 The IMD 114' and IMD 116 (shown in the diagram) are used for bidirectional wireless communication to program sensing and treatment delivery control parameters, as generally described above. IMD 114' and IMD 116 can be configured to communicate with each other via radio frequency communication, tissue conduction communication (TCC) or other communication methods to coordinate dual-chamber pacing and sensing in the dual-device system 110.
[0062] Figure 4This is a conceptual diagram of an IMD configured to sense cardiac electrical signals, sense patient acceleration signals, and deliver an ANS, based on some examples. Figure 4 Describes coupling to, as Figure 1 The leads 16 and 18 shown carry the IMD 14 of electrodes 20, 22, 24, 26, 28, and 30. However, it should be understood that, in combination Figure 4 The described circuits, components, and functionalities generally correspond to the circuits, components, and functions of an IMD and electrodes used to at least provide cardiac signal sensing, acceleration signal sensing, and ANS delivery. For example, in combination Figure 4 The described circuitry, components, and functions can be associated with leadless IMDs (e.g., those configured to deliver ANS) Figure 2 This corresponds to IMD 114 shown. In some other examples, it is combined with... Figure 4 The circuit components and functionalities described in the other flowcharts and diagrams presented herein can be found in multi-device systems (such as...) Figure 3 The dual-device system shown is distributed across multiple IMDs. For convenience, refer to... Figure 1 The IMD 14 pairs shown Figure 4 Describe it.
[0063] Figure 1 The electrodes 20, 22, 24, 26, 28, and 30 and / or the housing 15 shown in system 10 can be connected, for example, via a switching circuit included in the treatment delivery circuit 84 and the sensing circuit 86 to a device such as... Figure 4 The therapeutic delivery circuit 84 and / or cardiac electrical signal sensing circuit 86 (also referred to herein as "sensing circuit 86") are shown. Electronic circuitry encapsulated within housing 15 (in...) Figure 4 The concept shown in the middle (as an electrode, sometimes called a "can electrode") includes software, firmware, and hardware that work together to monitor cardiac electrical signals, determine when electrical stimulation therapy is needed, and deliver therapy on demand according to programmed therapy delivery algorithms and control parameters.
[0064] IMD 14 may include control circuitry 80, memory 82, treatment delivery circuitry 84, cardiac electrical signal sensing circuitry 86, telemetry circuitry 88, and sensor circuitry 92. Power supply 98 provides power to the circuitry of IMD 14 (including each of components 80, 82, 84, 86, 88, and 92) as needed. Power supply 98 may include one or more energy storage devices, such as one or more rechargeable or non-rechargeable batteries. The connections between power supply 98 and each of the other components 80, 82, 84, 86, 88, and 92 will be determined according to... Figure 4The overall block diagram is for understanding purposes, but is not shown for clarity. For example, power supply 98 may be coupled to one or more charging circuits included in treatment delivery circuitry 84 for charging holding capacitors included in treatment delivery circuitry 84, and to operate output circuitry to discharge these holding capacitors at appropriate times under the control of control circuitry 80 to generate electrical pulses according to the treatment protocol. Power supply 98 is also coupled as needed to components of cardiac electrical signal sensing circuitry 86 (such as sensing amplifiers, analog-to-digital converters, switching circuits, etc.), memory 82, telemetry circuitry 88, and sensor 92.
[0065] Figure 4 The various operating circuits shown represent the functionality included in IMD 14 and may include any discrete and / or integrated electronic circuit components implementing analog and / or digital circuitry capable of producing the functionality attributed to the IMD herein. Functionality associated with one or more circuits may be performed by separate hardware, firmware, and / or software components, or integrated within common hardware, firmware, and / or software components. For example, cardiac electrical signal sensing and analysis may be performed collaboratively by sensing circuitry 86 and control circuitry 80, and may include operations implemented in a processor or other signal processing circuitry included in control circuitry 80, which executes instructions stored in memory 82. Treatment delivery can be cooperatively performed by treatment delivery circuit 84 under the control of signals received from control circuit 80. These signals are used to control timing, pulse amplitude, pulse width, polarity, rate, electrode vector, and other treatment delivery parameters used by treatment delivery circuit 84 to generate and deliver electrical stimulation pulses. These electrical stimulation pulses may include ANS, cardiac pacing pulses, CV / DF shocks, impedance measurement drive signals, or via electrodes 20, 22, 24, 26, 28, 30 and / or Figure 1 Any other electrical pulse delivered by the housing 15 shown in the system.
[0066] The various circuits of the IMD 14 may include application-specific integrated circuits (ASICs), electronic circuitry, (shared, dedicated, or group) processors and memories executing one or more software or firmware programs, combinational logic circuits, state machines, hardware subroutines, or other suitable components or combinations of components that provide the described functionality. The specific form of the software, hardware, and / or firmware used to implement the functionality disclosed herein will be determined primarily by the specific system architecture employed in the IMD and the specific sensing, detection, and therapeutic delivery methods employed by the IMD. Given the disclosure herein, providing software, hardware, and / or firmware to implement the described functionality in the context of any modern medical device system is within the capabilities of those skilled in the art.
[0067] Memory 82 may include any volatile, non-volatile, magnetic, or electrically non-transitory computer-readable storage medium, such as random access memory (RAM), read-only memory (ROM), non-volatile RAM (NVRAM), electrically erasable programmable ROM (EEPROM), flash memory, or any other memory device. Furthermore, memory 82 may include a non-transitory computer-readable medium storing instructions that, when executed by one or more processing circuits, cause control circuitry 80 and / or other IMD components to perform various functions belonging to IMD 14 (or IMD 114 or a combination of IMD 114' and IMD 116 in system 110) or those IMD components. The non-transitory computer-readable medium storing instructions may include any of the media listed above.
[0068] The treatment delivery circuit 84 and sensing circuit 86 are electrically coupled to electrodes 20, 22, 24, 26, 28, 30 and / or housing 15, which can serve as a common or ground electrode for sensing electrical signals or delivering treatment, or as an active can electrode for delivering CV / DF electrical shock pulses. Therefore, housing 15 is conceptually shown as being coupled to... Figure 4 The electrodes of the treatment delivery circuit 84 and / or sensing circuit 86 are located in the treatment delivery circuit 84 and / or sensing circuit 86. The control circuit 80 communicates with the treatment delivery circuit 84 and sensing circuit 86, for example via a data bus, to sense cardiac electrical signals, detect cardiac rhythm, and control the delivery of cardiac electrical stimulation therapy in response to the sensed cardiac signal (or the absence of a cardiac signal).
[0069] The control circuit 80 may include a processor 81, a timing circuit 83, and a treatment control circuit 85. The processor 81 may be configured to process and analyze signals received from the sensing circuit 86, which may combine time intervals and / or timing-related signals received from the timing circuit 83 with signals received from the physiological sensor 92. The timing circuit 83 may generate a clock signal and include various timers and / or counters for determining the time interval between sensed cardiac event signals (e.g., sensed intrinsic P waves and / or R waves) and / or delivered pacing pulses associated with intrinsic myocardial depolarization. The timing circuit 83 may include various timers and / or counters for controlling the timing of delivered ANS, cardiac pacing pulses, and CV / DF shocks. The control circuit 80 may also include a treatment control circuit 85 configured to transmit signals to and receive signals from the treatment delivery circuit 84 to control and monitor electrical stimulation therapy delivered by the treatment delivery circuit 84 according to treatment control parameters (such as ANS control parameters described below).
[0070] Sensing circuitry 86 may be selectively coupled to electrodes 20, 22, 24, 26, 28, 30 and / or housing 15 to monitor the electrical activity of a patient's heart. Sensing circuitry 86 may be enabled to receive cardiac electrical signals from at least one sensing electrode vector selected from available electrodes, such as, for example, atrial electrical signals sensed via at least one RA lead electrode from RA lead electrodes 20 or 22 and ventricular electrical signals sensed via at least one RV lead electrode from RV lead electrodes 28 or 30. Sensing circuitry 86 may include switching circuitry for selecting which electrodes are coupled to sensing circuitry 86. For example, IMD 14 may include an atrial (A) sensing channel 87 for receiving signals from an electrode carried by RA lead 16 and a ventricular (V) sensing channel 89 for receiving signals from an electrode carried by RV lead 18. Figure 1 (As shown in the figure). In some examples, two, three, or more cardiac electrical signals from two, three, or more different sensing electrode vectors can be simultaneously received by corresponding sensing channels of sensing circuit 86 (e.g., atrial sensing channel 87 and ventricular sensing channel 89). Sensing circuit 86 can monitor cardiac electrical signals for sensing cardiac event signals, such as P waves accompanied by intrinsic atrial myocardial depolarization and R waves accompanied by intrinsic ventricular myocardial depolarization.
[0071] Each sensing channel 87 and 89 can be configured to amplify, filter, and digitize cardiac electrical signals received from selected electrodes coupled to the respective sensing channels 87 and 89 to improve the signal quality of sensed cardiac event signals such as P waves and R waves. The cardiac event sensing circuitry within sensing circuitry 86 may include one or more sensing amplifiers, filters, analog-to-digital converters (ADCs), rectifiers, threshold detectors, comparators, timers, or other analog and / or digital components. For example, amplified, filtered, and rectified signals sensed using RA lead electrodes 20 and / or 22 may be passed to a P-wave detector included in atrial sensing circuitry 87 for sensing P waves. The P-wave detector may include a sensing amplifier, comparator, and / or other electronic circuitry for applying a P-wave sensing threshold to the atrial electrical signal. In response to the atrial electrical signal crossing the P-wave sensing threshold, sensing circuitry 86 may pass an Asense signal to control circuitry 80 to indicate the timing of the sensed P wave.
[0072] The amplified, filtered, and rectified signal sensed using RV lead electrodes 28 and / or 30 can be transmitted to an R-wave detector included in the ventricular sensing channel 89 for sensing an R-wave. The R-wave detector may include a sensing amplifier, a comparator, and / or other electronic circuitry for applying an R-wave sensing threshold to the ventricular electrical signal. In response to the ventricular electrical signal crossing the R-wave sensing threshold, the sensing circuit 86 may transmit a Vsense signal to the control circuit 80 to indicate the timing of the sensed R-wave. The P-wave sensing threshold and the R-wave sensing threshold can be automatically adjusted by the sensing circuit 86 under the control of the control circuit 80, based on sensing threshold control parameters (such as various timing periods) and sensing threshold amplitude values that can be determined by the control circuit 80, stored in memory 82, and / or controlled by the hardware, firmware, and / or software of the control circuit 80 and / or the sensing circuit 86.
[0073] The Asense and Vsense signals received by the control circuit 80 from the sensing circuit 86 can be used by the control circuit 80 to determine the sensing cardiac event intervals. These sensing cardiac event intervals can be the PP interval (PPI) between Asense signals continuously received from the atrial sensing channel 87 (or from a delivered atrial pacing pulse to an Asense signal) and the RR interval (RRI) extending between Vsense signals continuously received from the ventricular sensing channel 87 (or between two consecutively delivered ventricular pacing pulses or between a delivered ventricular pacing pulse and a Vsense signal). The control circuit 80 may include timing circuitry 83 for determining various cardiac sensing event intervals, such as PPI and / or RRI, to determine the heart rate for controlling the ANS, as further described below in conjunction with the accompanying flowcharts and diagrams presented herein.
[0074] In some examples, sensing circuit 86 transmits digital electrocardiogram (EGM) signals to control circuit 80 for P-wave and / or R-wave morphology analysis to detect tachyarrhythmias. P-wave and / or R-wave morphology analysis may be performed in conjunction with cardiac event interval analysis, depending on the implemented tachyarrhythmia detection algorithm. The ANS techniques disclosed herein can be implemented in conjunction with various cardiac event signal sensing and tachyarrhythmia detection methods, and are not limited to any specific method for sensing P-waves and R-waves or for detecting tachyarrhythmias based on analysis of cardiac event intervals and / or cardiac signal waveform morphology.
[0075] Timing circuit 83 can be configured to control various timers and / or counters for setting various blanking periods, refractory periods, or other time intervals for sensing atrial and ventricular event signals by sensing circuit 86. The various timers and / or counters can be used to determine the time interval between received Asense and Vsense signals received from sensing circuit 86, and to control the timing of ANS, cardiac pacing pulses, and other electrical pulses generated by treatment delivery circuit 84. Timing circuit 83 can activate one or more timers or counters in response to receiving Asense and Vsense signals from sensing circuit 86 and in response to the delivery of atrial or ventricular pacing pulses by treatment delivery circuit 84, for scheduling subsequent pacing pulses and for determining various cardiac event intervals for controlling atrial pacing, ventricular pacing, ANS, and / or detecting tachyarrhythmias.
[0076] For example, timing circuit 83 can transmit the sensed cardiac event interval determined from the received Asense and Vsense signals (and the delivered ventricular pacing pulses) to processor 81 for determining heart rate. Processor 81 can be configured to count tachyarrhythmia intervals for detecting atrial or ventricular tachyarrhythmias. Timing circuit 83 can initiate a pacing escape interval in response to the Asense and Vsense signals received from sensing circuit 86 for controlling the timing of atrial and ventricular pacing pulses according to the pacing mode and pacing rate. As further described below, timing circuit 83 and treatment control circuit 85 can control treatment delivery circuit 84 to deliver an ANS pulse train according to ANS control parameters in response to a detected increase in heart rate, and can terminate ANS delivery in response to a decrease in heart rate.
[0077] Processor 81 may be implemented in control circuitry 80 for processing and analyzing signals received from sensing circuitry 86 and / or timing circuitry 83, as well as signals from physiological sensor 92, for detecting ANS triggering conditions. In some examples, processor 81 may include comparators and counters for counting PPIs and RRIs as tachyarrhythmia intervals determined by timing circuitry 83. For example, processor 81 may compare PPIs and / or RRIs with various heart rate thresholds for controlling ANS treatment delivery.
[0078] When the IMD 14 is configured to deliver a high-voltage CV / DF shock, the processor 81 can compare the RRI determined by the timing circuit 83 with the ventricular tachycardia detection interval and / or the ventricular fibrillation detection interval for the detection of ventricular tachyarrhythmias. Any of a variety of tachyarrhythmia detection methods can be implemented in the IMD performing the ANS method disclosed herein.
[0079] Control circuit 80 controls treatment delivery circuit 84 to generate an impedance measurement drive signal for delivery to the electrode pair. This impedance measurement drive signal can be a constant current or a constant voltage signal. The resulting voltage or current signal can be measured between selected recording electrode pairs by sensing circuit 86 and transmitted to control circuit 80 for determining the impedance measurement. In some examples, the impedance measurement can be used by control circuit 80 to monitor patient activity metrics. For example, minute ventilation or other respiratory metrics can be determined from the impedance signal to determine patient activity metrics. However, some patients experiencing POTS episodes may experience dyspnea or hyperventilation, interfering with the determination of activity metrics from the impedance signal measuring changes in chest impedance due to respiration. Therefore, according to the techniques described below, the activity metrics determined from the impedance signal may be reliable or unreliable for controlling ANS.
[0080] The therapeutic delivery circuit 84 may include at least one charging circuit and one or more charge storage devices (such as one or more holding capacitors) for generating electrical stimulation pulses for delivery to the patient's heart via a selected electrode vector. The therapeutic delivery circuit 84 may include a low-voltage therapeutic delivery circuit for generating relatively low-voltage cardiac pacing pulses and ANS pulse trains. The therapeutic delivery circuit 84 may include a high-voltage therapeutic delivery circuit for generating high-voltage CV / DF shock pulses. The low-voltage therapeutic delivery circuit may include a low-voltage charging circuit, one or more low-voltage holding capacitors, and a low-voltage output circuit for generating and delivering cardiac pacing pulses and ANS pulse trains, which may have programmable pulse voltage amplitudes, such as up to 12 volts, up to 10 V, up to 8 volts or less, or up to 5 volts or less. The cardiac pacing pulses may be delivered by the low-voltage therapeutic circuit in response to the expiration of a pacing escape interval or other pacing timing period determined by the control circuit 80. The cardiac pacing pulses may be delivered to provide bradycardia pacing, cardiac arrest pacing, ATP, post-shock pacing, etc.
[0081] The low-voltage charging circuit may include a charge pump for charging the low-voltage holding capacitor to a pacing voltage amplitude up to a multiple of the battery voltage of power supply 98 (e.g., up to three or four times the battery voltage). A state machine of control circuit 80 may use multiples of the battery voltage of power supply 98 to control the charging of the low-voltage holding capacitor to a programmed pacing voltage amplitude. The low-voltage output circuit may include one or more switching devices and an output or “end” capacitor through which the low-voltage holding capacitor can be discharged to deliver pacing pulses. The charged low-voltage holding capacitor can be discharged via the end capacitor by turning on an electrode selection switch after charging is complete to deliver pacing pulses to the selected cathode electrode via a return path using the selected anode electrode. Cardiac pacing pulses may be delivered as bipolar pacing pulses via an “end-to-loop” pacing electrode vector, for example, via RV end electrode 28 to RV loop electrode 30 in RV and / or via RA end electrode 20 to RA loop electrode 22 in RA, for successful capture and pacing of the heart.
[0082] A low-voltage treatment circuit can generate a pulse train for delivering an atrial subtraction angiotensin II (ANS) to alleviate or prevent post-angiotensin-deficiency syndrome (POTS). Each ANS pulse may have a pulse amplitude (e.g., up to 10 volts) and pulse width (e.g., up to 200 microseconds) less than the atrial myocardial capture threshold. The pulse amplitude, pulse width, number of pulses, and frequency of the pulses in the ANS pulse train are controlled by the treatment control circuit 85 according to ANS delivery control parameters to suppress the intrinsic atrial rate and / or AV node conduction, thereby reducing the likelihood of the patient experiencing POTS symptoms. Various ANS delivery control parameters that may be used by the control circuit 80 when controlling the delivery of ANS by the treatment delivery circuit 84 are described below.
[0083] In some examples, the treatment delivery circuit 84 may include a high-voltage (HV) treatment circuit, which may include an HV charging circuit, an HV holding capacitor, and an HV output circuit operably controlled by a signal from the control circuit 80, for charging and subsequently discharging the high-voltage capacitor for CV / DF shock delivery when the control circuit 80 detects ventricular tachycardia / fibrillation.
[0084] The IMD system operating according to the techniques disclosed herein includes circuitry comprising one or more physiological sensors 92 for sensing various physiological signals, such as acceleration signals, pressure signals, heart sound signals, temperature signals, etc. Sensor 92 includes an accelerometer 94 for sensing acceleration signals related to the patient's body movement and physical activity. It should be noted that POTS can occur without a change in blood pressure or without a decrease in blood pressure. Therefore, the methods disclosed herein may include detecting ANS treatment triggering conditions that do not include sensing blood pressure or blood pressure-related quantities used to detect changes in blood pressure.
[0085] Accelerometer circuitry 94 may be encapsulated within housing 15 of IMD 14. However, it should be appreciated that when IMD 14 is coupled to one or more medical electrical leads, accelerometer 94 may be carried by the leads (e.g., along the distal portion of the leads) and coupled to circuitry within housing 15 via electrical conductors. In various examples, the accelerometer may be a single-axis, two-axis, or three-axis accelerometer. Figure 4 In the diagram, accelerometer 94 is shown as a three-dimensional accelerometer with three sensing elements 93a, 93b, and 93c (collectively referred to as sensing elements 93). The sensing elements 93 may be orthogonal to each other, and each sensing element is aligned with a corresponding accelerometer axis A1, A2, or A3.
[0086] Each sensing element 93 of the accelerometer 12 is defined by a piezoelectric element, microelectromechanical system (MEMS) device, or other sensor element capable of generating an electrical signal in response to a change in acceleration applied to the IMD 14 and subsequently applied to the sensor element, for example by converting acceleration into a force or displacement of the accelerometer sensor element, which is then converted by the accelerometer sensor element into an electrical acceleration signal.
[0087] Each accelerometer sensor element 93a, 93b, and 93c generates acceleration axis signals (e.g., A1-axis, A2-axis, or A3-axis signals) corresponding to the vector components of acceleration applied to IMD 14 along the respective A1, A2, or A3 axis. Each accelerometer sensor element 93 generates a DC component corresponding to the vector component of gravity or other forces applied to the patient along the respective accelerometer axis. Each accelerometer sensor element generates an AC component along the respective axis corresponding to the acceleration vector component caused by patient motion or other accelerations experienced by the patient. Sensor circuitry 92 may include an ADC 95 and a filter / amplifier 96 for digitizing, amplifying, and filtering the accelerometer axis signals passed to control circuitry 80. Sensor circuitry 92 may include bandpass filters with bandpasses of 1 Hz to 30 Hz, 1 Hz to 20 Hz, or 1 Hz to 10 Hz (as an example) for generating body acceleration signals. The bandpass-filtered body acceleration signal is associated with acceleration caused by patient body movement, such as during changes in body position and patient movement. Each bandpass-filtered acceleration axis signal can be received by control circuitry 80 for detecting patient movement indicating a change from one body position to another. It should be noted that the bandpass-filtered signal is analyzed to detect patient movement associated with movement of the body from one position to another. In contrast, low-pass-filtered or DC acceleration axis signals representing the gravitational component along each axis can represent the patient's static body position, such as when lying down, sitting, standing, or in other body positions. As described below, control circuitry 80 can be configured to detect signal spikes in the bandpass-filtered acceleration signal that indicate patient movement when the patient changes body position. Processor 81 can be configured to analyze one, two, or all three accelerometer axis signals individually or in combination as signals for detecting patient body movement associated with changes in body position.
[0088] Patient body activity signals, whether identical or different bandpass filtered, can be transmitted from sensor circuitry 92 to control circuitry 80 to determine an activity metric related to the patient's level of body activity. The bandpass filter cutoff frequency used to generate the patient body activity signal may differ from the bandpass filter cutoff frequency used to detect the acceleration signal for detecting body positional movement. As further described below, the patient body activity metric can be determined by control circuitry 80 to detect ANS treatment trigger conditions and / or to control the termination of ANS delivery.
[0089] Control circuitry 80 can determine a patient body activity metric from an accelerometer signal at a desired frequency to determine a sensor-indicated pacemaker rate (SIR). The activity metric can vary between a minimum resting level and a maximum activity level associated with maximum physical exertion. In some examples, the activity metric is determined as an activity count. Control circuitry 80 may include a counter to track the activity count as the number of times the patient body activity signal from sensor circuitry 92 crosses a threshold during activity counting intervals (e.g., 0.5 seconds, 1 second, 2 seconds, or 3 seconds intervals). The count at the end of each activity counting interval is correlated with the patient's body movement during the activity counting interval and is therefore correlated with the patient's body activity. The threshold applied to the accelerometer signal (which causes the activity count to increase when crossed by the motion sensor signal) can be a default threshold, a programmable threshold, or an automatically adjusted threshold.
[0090] In other examples, the activity metric can be obtained from the accelerometer signal by integrating or summing the motion signal sampling points over an activity counting interval (e.g., a 0.5-second integration interval, a 1-second integration interval, or a 2-second integration interval, but longer or shorter intervals may also be used to determine the activity metric). Example methods for determining a patient's physical activity metric are generally disclosed in U.S. Patent No. 6,449,508 (Sheldon et al.), the entire contents of which are incorporated herein by reference.
[0091] Control circuit 80 receives rectified acceleration signals from sensor circuit 92 and determines patient physical activity metrics from the acceleration signals by summing the amplitudes of acceleration signal sampling points within the activity measurement time interval. The activity metrics can be converted into a target heart rate to meet the patient's metabolic needs. The target heart rate can be converted into an SIR based on a sensor-indicated rate (SIR) transfer function, which includes, for example, a lower rate setpoint, an activities of daily living (ADL) range, and a maximum higher rate. ADL corresponds to non-resting patient physical activities associated with normal daily activities, such as moving around the house, driving, and light physical tasks. Physical exertion above ADL levels corresponds to vigorous exercise and heavy physical tasks. Resting levels of activity metrics are expected when the patient is sleeping, sitting, or standing but relatively inactive. By determining the patient's physical activity metrics from the acceleration signals received from sensor circuit 92, control circuit 80 can convert the activity metrics into SIRs according to a transfer function stored in memory 82. During rate-response pacing mode, the treatment delivery circuit 84 can be controlled by the control circuit 80 to deliver atrial or ventricular pacing pulses at a rate-response pacing rate determined based on SIR.
[0092] Other types of sensors may be included in sensor circuitry 92, which generates signals related to the patient's physical activity or other physiological conditions. Such sensors may include heart sound sensors, oxygen sensors, pressure sensors, gyroscopes, etc.
[0093] When the IMD 114, 114', or 116 includes an accelerometer 94 and is implanted within or on a cardiac chamber, the control circuit 80 can process and analyze the acceleration signal for sensing ventricular mechanical event signals and / or atrial mechanical event signals. The control circuit 80 can determine the ventricular event interval between consecutively sensed ventricular mechanical event signals for determining the ventricular rate, and / or determine the atrial event interval between consecutively sensed atrial mechanical event signals for determining the atrial rate. Therefore, the determination of heart rate by the control circuit 80 for controlling ANS treatment is not necessarily limited to the processing and analysis of cardiac electrical signals. Other physiological sensor signals, including atrial and / or ventricular event signals, can be processed and analyzed to detect atrial and / or ventricular events accompanying atrial depolarization and atrial systole, and ventricular depolarization and ventricular systole, respectively, to determine heart rate and control ANS treatment according to the techniques disclosed herein.
[0094] Telemetry circuit 88 includes a transceiver and an antenna for communicating with external device 50 using RF communication or other communication protocols as described above. Figure 1 (As shown) Communication is performed. Control parameters used by control circuit 80 to sense cardiac event signals, sense acceleration signals, and control treatment delivery (including ANS) can be programmed into memory 82 via telemetry circuit 88. Under the control of control circuit 80, telemetry circuit 88 can receive downlink telemetry from external device 50 and send uplink telemetry to that external device.
[0095] Figure 5 This is a flowchart 200 illustrating a method for controlling an ANS by an IMD system, based on some examples. Figure 5 And other flowcharts presented in this article are usually combined Figure 1 The IMD 14 shown is described herein. However, it should be understood that the techniques disclosed herein for detecting ANS treatment triggering conditions and delivering ANS can be used in leadless IMDs (such as...). Figure 2 In the IMD 114 shown or in a multi-device system (such as Figure 3 It is implemented in the IMD system 110 shown.
[0096] At block 202, control circuitry 80 can monitor accelerometer signals received from sensor circuitry 92 to detect signal spikes indicating patient body movement during changes in body position. Control circuitry 80 can monitor heart rate to track baseline heart rate. When a signal spike is detected, the baseline heart rate can be compared to the post-spiking heart rate to detect an increase in heart rate (as described below in conjunction with block 208). The post-spiking heart rate increase can be detected to trigger ANS treatment delivery. At block 202, control circuitry 80 can monitor heart rate to detect atrial and / or ventricular tachyarrhythmias. At block 204, acceleration signal spikes can be detected when the heart rate is sinus rhythm (e.g., when control circuitry 80 does not detect atrial fibrillation, atrial flutter, ventricular tachycardia, or ventricular fibrillation).
[0097] In various examples, at block 202, control circuitry 80 can monitor a single accelerometer axis signal, two accelerometer axis signals, or all three accelerometer axis signals for detecting acceleration signal spikes. Control circuitry 80 can monitor accelerometer axis signals individually or in any combination; for example, it can sum or mathematically combine the weighted or unweighted absolute amplitudes of the A1, A2, and A3 axis signals, or use them to determine the acceleration vector. At block 204, control circuitry 80 can compare the accelerometer signals to a body position change motion standard.
[0098] To detect signal spikes that meet the criteria for postural change, control circuitry 80 can compare the difference between the i-th and in-th sampling points of the accelerometer signal with a threshold difference. In some examples, the difference is determined between consecutive sampling points (where n=1). In other examples, the difference can be determined between sampling points spaced apart by a specified time interval; for example, n can be 2, 3, 4, 5, 6, or other numbers of sampling points. The difference between sampling points of the accelerometer signal can be compared with a threshold difference to detect acceleration spikes indicating body movement during a postural change (e.g., from sitting to standing, from lying to standing, from lying to sitting, etc.). Control circuitry 80 can be configured at block 204 to detect acceleration signal spikes by detecting a threshold difference between two sampling points (or time intervals) of at least one accelerometer axis signal that are spaced apart by a specified number of sampling points (or time intervals). It should be noted that if the patient is relatively inactive after a postural change, the acceleration axis signal may reach a steady state after the spike. The steady-state acceleration signal after the peak may be different from or the same as the steady-state acceleration signal before the peak, because, for example, the patient may be in a resting or inactive state in an upright sitting position before the signal peak, and change to an upright standing position, but still remain relatively inactive.
[0099] In one example, by using the A1 axis sensing element, the A2 axis sensing element, and / or the A3 axis sensing element 93 (see...) Figure 4The output signal of each of the components is bandpass filtered to obtain the acceleration vector signal at each sampling point. The magnitude of the acceleration vector signal can be calculated as a mathematical combination of the A1, A2, and A3 acceleration signal components, for example, as the sum of the absolute amplitudes of the accelerometer axis signals or the sum of the squares of the amplitudes of the accelerometer axis signals. In other examples, the magnitude of the acceleration vector signal can be calculated as the Euclidean norm, for example, the square root of the sum of the squares of the three orthogonal A1-axis, A2-axis, and A3-axis signals corresponding to the x, y, and z components of the acceleration vector v, v:
[0100] During a positional change that may trigger a given patient's post-positional transition (POTS), the acceleration vector signal is expected to undergo a sudden change in magnitude within a short time interval (e.g., within 1 second or less) due to the patient's body movement during the positional change. In some examples, a derivative or difference signal (which may be a first-order or higher-order difference signal) can be determined and compared to a threshold to detect acceleration signal spikes indicative of patient body movement during the positional change. The derivative signal can be determined from a single A1-axis signal, A2-axis signal, or A3-axis signal, or a combination of axis signals. In some examples, the maximum peak value can be compared to a range of signal spike thresholds. The threshold or threshold range applied to one or more acceleration signals or their derivatives may depend on the calibration of the accelerometer and ADC range and can be tailored to individual patients by characterizing the patient's body movement during a known positional change (e.g., older patients may move more slowly and / or have different movement characteristic curves than younger patients during a given positional change, such as standing up from a lying or sitting position).
[0101] The magnitude, slew rate, and / or frequency of the acceleration signal or its derivative can be determined for detecting acceleration signal spikes in a bandpass (or high-pass) filtered accelerometer signal in response to changes in acceleration of the patient's body during movement from one body position to another. At block 204, the acceleration signal and / or its derivative can be analyzed by control circuitry 80 to determine if it meets the postural change motion criteria. In some examples, in addition to comparing the magnitude change of the acceleration vector signal (or one or more axis signals analyzed separately) to a spike detection threshold or threshold range, or as an alternative, the slew rate of the acceleration signal can be compared to a slew rate threshold. In some examples, acceleration signal spike detection may require detecting a first slew rate greater than a first threshold, followed by a second slew rate less than a second threshold. Postural change acceleration signal spikes can be associated with high slew rates in the acceleration signal as the patient moves between one body position and another, followed by a relatively stable acceleration signal when the patient's body activity level is relatively inactive after the postural change. In this way, relatively high-frequency spikes in body acceleration signals can be detected when the acceleration signal meets the postural change movement criteria used to trigger ANS treatment.
[0102] To capture acceleration signal spikes caused by changes in body position, the three-dimensional (or two-dimensional or single-axis) accelerometer signal can be bandpass filtered to remove DC components and high-frequency noise. As an example, the accelerometer signal can be filtered using a 1Hz to 30Hz bandpass filter or a 1Hz to 3Hz bandpass filter to obtain an output signal that includes acceleration caused by body movement during a change in position. The filter can be an adjustable filter whose cutoff frequency is set to be customized for individual patients to optimize acceleration signal spike detection performance, for example, to reduce false spike detection or missed true spike detection associated with body movement during a change in position that may trigger a given patient's POTS. The threshold applied to the acceleration signal for detecting acceleration signal spikes can also be adjustable to be customized for a given patient, for example, taking into account the patient's or caregiver's ability to use a combination of... Figure 1 The described external device 50 confirms a POTS attack. For example, a threshold can be adjusted when no acceleration signal spike associated with a patient-confirmed POTS attack is detected. In some examples, a threshold range with maximum limitations can be applied to the acceleration signal to avoid detecting acceleration signal spikes with higher magnitudes and / or higher transition rates than expected during body movements associated with postural changes. The threshold or value range applied to the acceleration signal for detecting signal spikes can be stored in memory 82 as a postural change movement criterion.
[0103] It should be noted that the techniques disclosed herein do not necessarily require determining the patient's body position. Some IMDs can be configured to determine the patient's body position based on the analysis of a low-pass filtered acceleration signal (or an averaged or DC acceleration signal) representing the gravitational component along the accelerometer axis. The techniques disclosed herein do not necessarily require determining the patient's body position. Instead, control circuitry 80 is configured to detect patient body movements associated with a change in body position from a first body position or position to a second body position or position by detecting acceleration signal spikes that meet the movement criteria for a change in body position. The first and second body positions may be undetermined or unknown.
[0104] Upon detection of an acceleration signal spike, control circuitry 80 can monitor the heart rate at block 208 for a specified time period following the acceleration spike to detect a threshold heart rate increase. In some examples, a heart rate increase of at least 20, 25, 30, 35, or 40 bpm may be required after signal spike detection to trigger ANS treatment. The threshold heart rate increase may occur within 20, 30, 45, or 60 seconds of the detected signal spike. The threshold heart rate increase may be based on the heart rate exactly before or immediately after spike detection.
[0105] Therefore, control circuit 80 can receive Asense and / or Vsense signals from sensing circuit 86 and use them to determine sensed cardiac event intervals (e.g., PPI or RRI), which can be compared with corresponding heart rates to detect a threshold heart rate increase after signal spike detection. Control circuit 80 can determine the mean, median, maximum, minimum, or other representative sensed cardiac event intervals from the sensed cardiac event intervals. For example, as an example, the median sensed cardiac event interval can be determined from the most recent 3, 4, 6, 8, 10, 12, 20, or 30 PPIs or RRIs. The baseline median sensed cardiac event interval can be determined as the most recent median sensed cardiac event interval determined before the detection of an acceleration signal spike or the earliest median heart rate interval determined after the detection of an acceleration signal spike. The control circuit 80 can determine an updated median sensed cardiac event interval at a specified time interval following the detection of the acceleration spike (e.g., 10, 15, 20, 30, 45, or 60 seconds after the spike detection). In other examples, the control circuit 80 can determine an updated median sensed cardiac event interval at multiple time points following the detected signal spike (e.g., every 5 or 10 seconds after the detected signal spike, up to one to two minutes).
[0106] At block 208, the difference between the heart rate corresponding to the updated sensed cardiac event interval following the detected signal spike and the baseline heart rate corresponding to the baseline sensed cardiac event interval can be compared with a heart rate change threshold. When the heart rate does not increase by at least the threshold amount, control circuitry 80 can return to block 202 and wait for subsequent spike detection. If the maximum spike post-interval has not expired, control circuitry 80 can continue to determine an updated sensed cardiac event interval until the maximum spike post-interval expires for detecting a threshold heart rate increase. For example, a sudden increase in heart rate corresponding to a POTS episode may occur within 2 minutes or less, or within 1 minute or less. If no threshold heart rate change is detected within the maximum spike post-interval, POTS may not occur, making ANS treatment unnecessary. Therefore, when a signal spike is detected at block 204, control circuitry 80 can start a post-spiking timer, during which heart rate is monitored for detecting a threshold heart rate increase.
[0107] If a threshold heart rate increase is detected after an acceleration spike is detected, control circuitry 80 may control treatment delivery circuitry 84 to initiate ANS treatment at block 212. In some examples, in addition to detecting a threshold heart rate increase, or alternatively, control circuitry 80 may determine whether the heart rate is greater than a minimum heart rate for triggering ANS treatment. In an exemplary example, control circuitry 80 may determine that the ANS triggering condition is met when the heart rate increases by at least 30 bpm within one minute after the detected acceleration signal spike and the heart rate is at least 90 bpm, 100 bpm, 110 bpm, 120 bpm, or 130 bpm (as an example).
[0108] When the expected ANS triggering condition associated with a POTS attack is met, ANS treatment can be delivered by the treatment delivery circuit 84 as a burst of pulses (e.g., following the Asense signal received from the sensing circuit 86) or as a continuous, relatively high-frequency burst of pulses. The following example combines... Figure 8 , Figure 10 and Figure 11 An example ANS pulse train and ANS delivery control parameters are described using the treatment delivery circuit 84 to deliver ANS.
[0109] In some examples, the ANS can be delivered for a specified time interval or a specified number of cardiac cycles before being terminated. In other examples, such as Figure 5As shown, control circuitry 80 can monitor patient physical activity and / or heart rate for detecting ANS termination conditions. For example, at block 214, control circuitry 80 can monitor accelerometer signals received from sensor circuitry 92 for detecting an increase in patient physical activity. Control circuitry 80 can determine a patient activity metric from the accelerometer signal. This activity metric can be an activity count as generally described above or a SIR based on the activity count. If the activity metric is greater than a non-resting activity threshold (which indicates an increase in patient physical activity after an acceleration signal spike is detected), control circuitry 80 can initiate termination of ANS treatment at block 218. The non-resting activity threshold can be a specified activity level threshold stored in memory 82. The non-resting activity threshold can correspond to physical exertion greater than a resting level threshold or an ADL threshold. In some examples, this threshold can be set based on a baseline patient physical activity metric determined by control circuitry 80 from the accelerometer signal most recently before the detection of the acceleration signal spike. In other examples, the baseline patient physical activity metric can be determined by the control circuitry as the earliest activity metric determined after the signal spike detection. When activity measures are determined at specified time intervals (e.g., every two seconds), the baseline activity measure can be the activity measure determined temporally closest to the detected acceleration signal spike (whether before or after that spike). In an illustrative example, if the baseline SIR is 60 bpm at the time of acceleration signal spike detection (or exactly before or after it), and the SIR increases from the baseline SIR by 10 bpm, 20 bpm, 25 bpm, 30 bpm, 40 bpm, or other specified increase during ANS delivery, then control circuitry 80 can detect the increased patient physical activity at box 214.
[0110] In response to the detection of increased patient physical activity, control circuitry 80 may terminate the ANS immediately or gradually at block 218 to allow the heart rate to physiologically increase in response to the increased physical activity of the patient. In some examples, as combined below Figures 8 to 10Further described, one or more ANS delivery control parameters may be progressively decreased until ANS treatment is completely terminated. The rate of progressive decrease of the control parameters may be relatively faster or slower, depending on the level of the increased activity metric determined at box 214. As the ANS delivery control parameters progressively decrease, the treatment delivery circuit 84 may deliver atrial and / or ventricular pacing pulses according to a rate-response pacing rate determined by the control circuit 80 from the SIR. In other examples, as ANS progressively decreases, ventricular pacing pulses may be delivered according to the rate-response rate of the determined SIR or at a programmed lower pacing rate until the intrinsic heart rate exceeds the pacing rate. When ANS is completely terminated, the intrinsic heart rate may physiologically respond to the increased physical activity, such that the rate-response pacing pulses are suppressed by the sensed intrinsic P wave and / or R wave. After ANS treatment is terminated, the control circuit 80 may return to box 202 to monitor for the next acceleration signal spike.
[0111] When no increased patient physical activity is detected at box 214, control circuitry 80 may determine at box 216 whether a decreased heart rate has been detected. A decrease in heart rate can be a return to baseline heart rate or a return to a threshold heart rate greater than baseline, for example, a baseline heart rate plus 10 bpm to 20 bpm. Increased parasympathetic tone is expected during ANS treatment to lower the heart rate to a normal resting (or relatively low-activity) heart rate. A decrease in heart rate may be detected in response to a sensed intrinsic rate being less than a threshold rate (e.g., less than 70 bpm, 80 bpm, 90 bpm, or 100 bpm). A decrease in heart rate may be detected in response to treatment delivery circuitry 84 delivering atrial or ventricular pacing at a programmed lower rate interval. A decrease in heart rate may be detected when the atrial or ventricular rate decreases by at least a threshold change (e.g., at least 10 bpm, 15 bpm, 20 bpm, 25 bpm, or 30 bpm lower than the heart rate detected as an increased heart rate). When control circuit 80 detects a decreased heart rate at block 216, control circuit 80 may control treatment delivery circuit 84 to terminate ANS treatment at block 218. In some examples, ANS treatment may be terminated abruptly, but in other examples, it may be terminated gradually to avoid sudden changes in voluntary tone and heart rate.
[0112] For example, ANS treatment can be gradually reduced by progressively decreasing ANS treatment delivery control parameters (such as pulse amplitude, pulse width, and / or the number of pulses per pulse train, as an example). When the ANS treatment control parameters have reached their minimum control parameter values (e.g., minimum pulse amplitude, pulse width, or minimum number of pulses per pulse train) at block 218, the treatment delivery circuit 84 can stop ANS delivery. The control circuit 80 can then return to block 202 to resume monitoring another acceleration signal spike. Although in Figure 5Not shown, but as ANS treatment gradually decreases, control circuit 80 can continue to monitor the cardiac event interval to detect a return of heart rate to or above the increased heart rate threshold. Control circuit 80 can respond by increasing one or more ANS delivery control parameters within a specified time interval, and then resuming the gradual decrease of ANS treatment, allowing a gradual return to a physiologically normal heart rate to occur.
[0113] Figure 6 This is a flowchart 300 of a method for ANS treatment controlled by an IMD, according to another example. At block 302, control circuitry 80 may monitor patient physical activity, for example, by determining an activity metric from an accelerometer signal according to any of the examples described above. When the activity metric is greater than a low activity threshold, control circuitry 80 may not detect an acceleration signal spike necessary to trigger ANS treatment. The low activity threshold may correspond to an activity level at least above the resting level and may correspond to at least ADL or more vigorous activity. The signal spike present in the acceleration signal may be caused by the patient's physical activity. When the activity metric is greater than the low activity threshold, as determined at block 304, it may not be desirable to suppress the increase in heart rate by increasing parasympathetic tone.
[0114] In response to an activity metric exceeding a low activity threshold, control circuitry 80 may disable acceleration signal spike detection at block 306. In other examples, any signal spikes detected by control circuitry 80 may be ignored for the purpose of triggering ANS treatment. Control circuitry 80 may continue to monitor patient activity at block 302, but may not detect ANS treatment trigger conditions or may disable ANS delivery when the activity metric exceeds a low activity threshold (block 304).
[0115] When the activity metric is less than a low activity threshold, control circuitry 80 may enable acceleration signal spike detection at block 308. In other examples, when the activity metric is less than the low activity threshold, ANS treatment for delivery may be enabled at block 308 in response to the detection of an ANS trigger condition. Generally, when the activity metric is equal to or greater than the low activity threshold, the detection of ANS treatment trigger conditions and the initiation of ANS treatment may be disabled, and when the activity metric is less than the low activity threshold, the detection of ANS treatment trigger conditions and the initiation of ANS treatment may be enabled. The low activity threshold applied to the activity metric at block 304 may be customized for a given patient based on the activity characteristic curve of the given patient and / or the activity characteristic curve associated with POTS. When the activity metric meets the low activity threshold (e.g., equal to or greater than the low activity threshold), ANS may be effectively disabled by disabling or ignoring acceleration signal spike detection or by directly disabling ANS treatment delivery. When the patient's activity metric is less than the low activity threshold, ANS treatment may be enabled, for example, by enabling acceleration signal spike detection at block 308 or responding to acceleration spike detection.
[0116] At block 310, control circuitry 80 monitors the received acceleration signal for detecting acceleration signal spikes, according to any of the examples described herein. If no signal spike is detected, control circuitry 80 may return to block 302 and continue monitoring the patient's physical activity.
[0117] When the activity metric at box 304 is less than the low activity threshold and an acceleration signal spike is detected at box 310, the control circuit 80 may monitor the sensing event signal received from the sensing circuit 86 as described above, for use in detecting a threshold heart rate increase after the signal spike detection. (Based on the above...) Figure 5 Any of the examples described can detect an increase in heart rate at box 312.
[0118] If no increase in heart rate is detected at box 312, control circuitry 80 may return to box 302 to continue monitoring patient body activity and wait for the next spike detection when the activity metric is below a low activity threshold. The currently detected signal spike may or may not be caused by a genuine change in patient position, but in either case, ANS treatment may not be delivered if no increase in heart rate is detected. In other examples, the heart rate check at box 312 may be omitted in some cases. When relatively low patient body activity is detected and an acceleration signal spike is detected, treatment delivery circuitry 84 may be configured to initiate ANS treatment in some cases. ANS can be initiated in patients who frequently experience POTS in response to changes in position to provide preventative treatment without waiting for the expected tachycardia.
[0119] exist Figure 6In the example, before initiating ANS treatment, control circuitry 80 may determine at block 314 whether an activity metric has increased. At block 310, an acceleration signal spike may have been detected when the activity metric is below a low activity threshold, but the patient may become physically active (e.g., begin walking, jogging, running, or engaging in other physical activity) after a postural change that may have caused the signal spike. The detected signal spike may be accompanied by the onset of physical activity for which an increase in heart rate is appropriate. At block 314, an increase in patient physical activity can be detected by comparing the activity metric to the same low activity threshold applied at block 304, or to a different, relatively higher activity threshold associated with increased physical activity that is expected to result in sinus tachycardia or at least an increase in the intrinsic heart rate. At block 314, an activity count, SIR, or other physical activity metric may be compared to the increased activity threshold. In various examples, the increased activity threshold applied at block 314 may be a specified value stored in memory 82, which can be programmably customized based on the activity characteristic curve of a given patient. In some cases, the control circuit 80 may determine the increased activity threshold based on a baseline activity metric determined at, or just before or after, signal spike detection. In yet other examples, the increased activity threshold may be a specified percentage or a specified difference from the low activity threshold.
[0120] exist Figure 6 In the example, the triggering condition for initiating ANS is therefore an initial low physical activity (the "Yes" branch of box 304), during which an acceleration signal spike is detected (the "Yes" branch of box 310), optionally followed by a detection of an increase in heart rate (the "Yes" branch of box 312), without any accompanying increase in patient physical activity (the "No" branch of box 314). When the sequence and combination of conditions for triggering ANS are met, the treatment delivery circuit 84 may initiate ANS at box 316. The control circuit 80 may detect an increased heart rate at a specified time interval after the spike, but the activity metric does not meet the increased activity threshold. For example, the control circuit 80 may wait at least 20 seconds, 30 seconds, 45 seconds, or one minute after the detected signal spike to verify that the activity metric does not meet the increased activity threshold before initiating ANS treatment at box 316.
[0121] After the ANS is activated, the control circuit 80 can monitor activity metrics at block 318 to detect increases in physical activity that may require a physiological increase in heart rate, as described above. Figure 5As described. If the activity metric increases at box 318, the control circuit 80 can control the treatment delivery circuit 84 at box 320 to progressively decrease the ANS treatment according to the level of physical activity. In some examples, the ANS delivery control parameter can progressively decrease at a faster rate when the activity metric is relatively high at box 318, and at a relatively slower rate when the activity metric is relatively low.
[0122] In an illustrative example, without intended limitation, if the activity metric is greater than the high exertion threshold, the ANS pulse amplitude may gradually decrease to a minimum amplitude over 15 seconds, and if the activity metric is greater than the ADL threshold but less than the high exertion threshold, the ANS pulse amplitude may gradually decrease to a minimum amplitude over 30 seconds. In another example, if the SIR is greater than 110 bpm, the ANS pulse amplitude may gradually decrease to a minimum amplitude over 15 seconds, and if the SIR is greater than 80 bpm, the ANS pulse amplitude may gradually decrease to a minimum amplitude over 30 seconds. Other time intervals for the gradual decrease of the ANS delivery control parameters and the corresponding threshold activity metric values may be stored in memory 82 and used by control circuitry 80 to control treatment delivery circuitry 84 to gradually decrease the ANS at block 320 in a manner proportional to the activity metric value. As an example, and not intended to limit, ANS treatment may gradually decrease to complete termination over 5 seconds, 10 seconds, 15 seconds, 20 seconds, 30 seconds, 45 seconds, or 60 seconds. The gradual decrease intervals may be programmed by the clinician. The gradually decreasing interval can be adjusted by the control circuit 80, for example, if a short interval causes a sudden return of a rapid heart rate, it can be adjusted to a longer interval.
[0123] While the treatment delivery circuit 84 is progressively decreasing the ANS, the control circuit 80 may return to block 318 to continue monitoring the activity metric. If the activity metric increases more significantly during the progressive decrease process at block 318, the control circuit 80 may control the treatment delivery circuit 84 to progressively change one or more ANS delivery control parameters at a faster progressive decrease rate. If the activity metric decreases at block 318 while the ANS is progressively decreasing, the treatment delivery circuit 84 may continue to progressively decrease the ANS delivery control parameters at the same rate until the ANS is completely terminated. In other examples, after the progressive decrease of ANS treatment has been initiated, the control circuit 80 may control the treatment delivery circuit 84 to reduce the rate of progressive decrease of the ANS delivery control parameters in response to a decrease in the activity metric determined at block 318.
[0124] Once the ANS delivery control parameters have reached their minimum, effectively terminating ANS treatment delivery (as determined at box 326), control circuitry 80 can return to box 302 to resume monitoring for relatively low levels of physical activity, during which acceleration signal spikes can be detected to trigger another ANS treatment. If ANS has not completely terminated at box 326, control circuitry 80 can continue monitoring activity metrics at box 318 and heart rate at box 322.
[0125] As mentioned above Figure 5 As described, control circuitry 80 can monitor heart rate during ANS delivery at block 322, for example, by monitoring the cardiac sensing event interval determined in the Asense and / or Vsense signals received from sensing circuitry 86 (and / or cardiac pacing delivered by treatment delivery circuitry 84) to detect a decreased heart rate. It should be understood from flowchart 300 that control circuitry 80 can monitor both activity metrics and heart rate in parallel or simultaneously, without necessarily in the following manner: Figure 6 The order of boxes 318 and 322 in the diagram is as shown.
[0126] If a decreased heart rate is detected at box 322, control circuitry 80 may control treatment delivery circuitry 84 to gradually terminate the ANS at box 328. One or more ANS delivery control parameters may be gradually decreased over a specified time interval (e.g., 30 to 60 seconds). As the ANS gradually terminates, control circuitry 80 may continue to monitor patient physical activity at box 318 and heart rate at box 322 until the ANS is completely terminated as determined at box 326. For example, complete termination of the ANS may be achieved when the decreased control parameter reaches zero or a minimum value. If an increase in activity metric is detected at box 318 as the ANS gradually terminates, treatment delivery circuitry 84 may perform a proportional gradual decrease at box 320, which may be faster than a gradual termination performed in response to a decreased heart rate. A faster gradual decrease in response to increased activity allows the intrinsic heart rate to increase appropriately to support the increased activity. If the heart rate increases during the gradual termination but the activity metric does not increase, the treatment delivery circuit 84 can return to box 316 to increase the ANS delivery control parameter again.
[0127] In some examples, such as Figure 6As shown, if the maximum ANS delivery time is reached without a detected decrease in heart rate (as determined by control circuitry 80 at block 326), treatment delivery circuitry 84 may terminate the ANS at block 328. In some examples, control circuitry 80 may determine whether the heart rate has decreased by at least a certain amount from the increased heart rate detected at block 312, for example, 5 to 10 heart beats per minute or at least 10%, 15%, or 20%. Control circuitry 80 may determine whether at least a certain degree of heart rate decrease has occurred to verify that a therapeutic response to the ANS has occurred. If no heart rate decrease occurs within a specified number of cardiac cycles (e.g., 10 to 30 heart beats) or a specified time interval (e.g., 10 to 30 seconds), treatment delivery circuitry 84 may begin terminating the ANS at block 328. However, control circuitry 80 may verify that the heart rate does not reach a tachycardia rate or other high threshold rate as the ANS gradually terminates to avoid POTS occurring as the ANS gradually decreases. If the heart rate increases, the ANS control parameters may be increased again. Therefore, the gradual termination process may include increasing the ANS control parameter once or multiple times, followed by gradually decreasing the ANS control parameter again. Once the ANS is completely terminated, the control circuit 80 may return to block 302.
[0128] Figure 7 Figure 400 shows example accelerometer axis signals 402, 404, and 406 that can be received by control circuit 80. A1 axis signal 402, A2 axis signal 404, and A3 axis signal 406 can be received along IMD 14 (see Figure 400). Figure 4 Accelerometer sensor elements 93, arranged orthogonally along the accelerometer 94, sense acceleration. In this example, an acceleration signal spike 410 caused by the patient's body movement during a change in body position is observed in each of the three axis signals 402, 404, and 406. In the example shown, the patient moves from a sitting position to a standing position. Before signal spike 410, the average amplitude of each signal 402, 404, and 406 corresponds to the gravitational component along the corresponding axis of the accelerometer. After signal spike 410, each acceleration signal 402, 404, and 406 varies as the patient's body moves during the position change interval 412. As the patient moves to a standing position, the acceleration force applied to the accelerometer sensor element 93 changes due to variations in the alignment between each sensor element and gravity, as well as the patient's movement, causing a change in each of the three axis signals 402, 404, and 406 during the position change interval 412. Signal spike 410 may indicate the start of the position change.
[0129] After stabilization to the new position (standing in this case), accelerometer axis signals 402, 404, and 406 can return to the average amplitude observed before the signal spike 410. The gravitational force acting on each accelerometer axis of the IMD 14 implanted in the chest or trunk can be substantially equal when the patient is sitting upright (before the spike) and when the patient is standing still (after the spike). Therefore, if the patient is now standing still and relatively inactive, each axis signal can be expected to return to the pre-spike acceleration signal amplitude, or at least to the relative steady-state amplitude, after the post-positional change interval 412 and during the post-positional change interval 414. However, it should be recognized that the patient may sit down or change position again after the signal spike is detected, for example, if subsequent physical activity occurs. Once the acceleration signal spike is detected, in some examples, subsequent postural changes and physical activity can be ignored because heart rate and patient physical activity are monitored once the initial signal spike is detected to control ANS treatment.
[0130] Control circuit 80 can detect acceleration signal spikes 410 by detecting a slew rate greater than a threshold slew rate of axis signals 402, 404, or 406. As described above, control circuit 80 can detect acceleration signal spikes 410 by comparing the amplitudes of sampling points spaced apart by a specified sampling time. For example, acceleration signal spike 410 can be detected when the difference between the i-th sampling point and the in-th sampling point is greater than a threshold difference. In some examples, control circuit 80 can analyze single-axis signals 402, 404, or 406 for detecting signal spikes 410. In the example shown, A2 axis signals 404 and A3 axis signals 406 exhibit larger signal spikes than A1 axis signal 402. For a change in body position towards an upright position that may be associated with POTS, a given one of the A1 axis signal, A2 axis signal, or A3 axis signal may exhibit a larger signal spike. The axis signals 402, 404, or 406, which mark body movement during postural changes, can depend on the orientation of IMD 14 relative to the patient's body.
[0131] In some examples, the axis signal used by control circuitry 80 to detect signal spikes can be programmable. After IMD implantation or during follow-up, when the patient is instructed to change body position (e.g., stand up from a sitting position), control circuitry 80 can send the axis signal via telemetry circuitry 88. Clinicians can observe the axis signal to select a programmed axis signal 402, 404, or 406 for control circuitry 80 to use in detecting signal spikes.
[0132] In some examples, the axis signal used by control circuit 80 to detect signal spikes can be selected by control circuit 80 based on its analysis of axis signals 402, 404, or 406. For example, control circuit 80 can detect signal spikes based on one or all three individual axis signals and can determine which of the three axis signals 402, 404, or 406 has the highest absolute peak amplitude and / or the highest slew rate. When a signal spike 410 is detected based on all three axis signals, the axis signal determined to have the highest peak amplitude and / or the highest slew rate can be selected as the axis signal for triggering ANS delivery signal spike detection. By selecting one axis signal for signal spike detection, IMD power supply 98 can be saved because only one sensor element 93a, 93b, or 93c needs to be powered to monitor signal spike 410.
[0133] In other examples, control circuitry 80 may use a combination of all three axis signals 402, 404, and 406. Control circuitry 80 may, for example, sum the magnitudes (absolute amplitudes) of each axis signal 402, 404, and 406 at each sampling time point (e.g., sampled at 128 Hz, 256 Hz, or other sampling rates) to obtain a combined acceleration signal, which is analyzed to detect signal spikes 410.
[0134] In some examples, such as combination Figure 6 As described, control circuit 80 may require that the activity metric be less than a low activity threshold before the detection of signal spike 410 in order to trigger ANS treatment. Additionally or alternatively, control circuit 80 may require that the activity metric be less than a low activity metric or not increase after the postural change interval 412 in order to trigger ANS treatment. For example, control circuit 80 may determine whether the activity metric determined after signal spike 410 is less than an increased activity threshold, as described above. Figure 6 As described in (box 314). When the activity metric is greater than the increased activity threshold, ANS delivery may not be triggered because an increase in sinus heart rate is expected.
[0135] In some examples, control circuitry 80 may determine the mean acceleration signal amplitude during the post-positional change interval 414 for comparison with the baseline (pre-peak) mean signal amplitude. If the mean signal amplitude has not returned to a threshold range of the baseline mean signal amplitude during the post-positional change interval 414, control circuitry 80 may not trigger ANS treatment. In other examples, the frequency content of the acceleration signal may be analyzed after the peak to verify the attainment of a steady state, which indicates relative inactivity of the patient after the detection of the signal peak. In some examples, control circuitry 80 may not analyze the acceleration signal amplitude during the post-positional change interval 412 corresponding to body movement during the post-positional change to determine whether to trigger ANS.
[0136] Figure 8 This is a diagram 450 illustrating the ANS treatment triggering conditions and the timeline of ANS delivery based on some examples. An acceleration (ACC) signal 451, an activity (ACT) measure 462, a heart rate (HR) 472, and an ANS pulse train 480 are shown. The acceleration signal 451 can be a single-axis signal or represent a combination of axis signals, such as the sum of time-aligned axis signal samples.
[0137] Control circuitry 80 may determine activity metric 462 from the acceleration signal received from accelerometer 212, according to any of the examples described above. In some examples, activity metric 462 may represent an activity count. In other examples, activity metric 462 may represent a SIR determined from the activity count, which may be used by control circuitry 80 to determine the rate response pacing rate (if rate response pacing is enabled). The activity count (and the corresponding SIR) may be determined every 0.5 seconds, 1 second, 2 seconds, or other desired activity monitoring intervals.
[0138] HR 472 can be determined as a heart rate corresponding to a moving average, median, or other representative sensed cardiac event interval, or it can be determined as a heart rate corresponding to each individual sensed cardiac event interval (e.g., each PPI or RRI) that is determined when an Asense or Vsense signal is received from the sensing circuit 86.
[0139] Acceleration signal spike 452 is detected by control circuit 80. Control circuit 80 can detect signal spike 452 when recent activity measure 462 is less than low activity threshold 464, indicating that the patient was at rest or relatively inactive when the postural change causing signal spike 452 occurred. (See also...) Figure 6 As described, when the activity metric 462 is less than the low activity threshold 464, acceleration signal spike detection can be enabled, so that the signal spike 452 can be detected by the control circuit 80 for use in triggering ANS treatment.
[0140] Control circuit 80 may initiate a post-peak time interval 454 during which HR 472 is monitored to detect an increase indicating the start of POTS. HR may be compared by control circuit 80 to an HR change threshold 474. The HR change threshold 474 may represent a threshold increase 477 from a baseline HR 476. Control circuit 80 may determine the baseline HR 476 at the time of the most recent activity metric 462 prior to the detection of the signal spike 452 or at the time of the signal spike detection 452. The HR change threshold 474 may be determined by control circuit 80 by adding a threshold increase 477 (which may be stored in memory 82) to the baseline HR 476. In some examples, the threshold increase 477 is 30 bpm, but this is not intended to limit.
[0141] Additionally or alternatively, when HR 472 meets a high heart rate threshold 475, the control circuit 80 may detect an increased HR, which may be a condition other than meeting an HR change threshold 474. The high heart rate threshold 475 may be between 90 bpm and 140 bpm and may be programmed according to a given patient's heart rate characteristic curve. The high heart rate threshold 475 may be higher or lower than the HR change threshold 474 at different times, depending on the baseline HR 476 at the time of signal spike detection. In some examples, the control circuit 80 may detect an increased HR to trigger ANS delivery when the baseline HR increases by at least 30 bpm (or other threshold change) within the post-spiking time interval 454 and at least reaches the high heart rate threshold 475.
[0142] In the example shown, HR 472 increases from baseline HR 476 by at least a threshold change 477 within the post-peak time interval 454, thus exceeding the heart rate threshold 474. HR 472 also meets a high heart rate threshold 475 within the post-peak time interval 454. Control circuit 80 determines that the ANS triggering condition is met and controls treatment delivery circuit 84 to initiate an ANS pulse train 480.
[0143] In this example, the ANS pulse train 480 is a continuous pulse train delivered according to ANS delivery control parameters. For example, the ANS pulse train 480 may be delivered independently of the timing of the Asense or Vsense signals. In some examples, the ANS pulse train 480 may be initiated upon receipt of an Asense signal and delivered continuously until a termination condition is detected.
[0144] Based on the ANS delivery control parameters stored in memory 82, the pulses of the ANS pulse train 480 have a starting pulse amplitude 482, a pulse width 484, and a pulse period 486, which defines the frequency of the pulse train 480. It should be understood that, for clarity, the illustrated pulse train 480 is scaled to illustrate the characteristics of each pulse within the pulse train. Therefore, the pulse train 480 may not be illustrated on time scale relative to HR variation, activity measurement 462, acceleration signal 451, and post-peak time interval 454.
[0145] In this example, after initiating the ANS pulse train 480, the activity metric 462 remains below the low activity threshold 464. The ANS pulse train 480 is not adjusted based on the activity metric 462 if no increase in activity metric 462 occurs during the ANS pulse train 480. In the example shown, the control circuit 80 detects a decrease in HR 472 during the ANS pulse train 480. In some examples, if HR 472 drops to or below the normal HR threshold 478, the treatment delivery circuit 84 can begin terminating the ANS by gradually decreasing one or more ANS delivery control parameters. For illustration, in response to HR 472 dropping below the normal HR threshold 478 during ANS treatment delivery, the pulse amplitude 482 gradually decreases according to the gradual decrease rate 490. When the pulse amplitude reaches a minimum amplitude (which may be zero or greater than zero), the ANS can be completely terminated. In other examples, instead of reducing the pulse amplitude, or in addition to reducing the pulse amplitude, the pulse width 484 can be reduced (with or without an increase in the inter-pulse interval to maintain or increase the pulse train frequency, respectively).
[0146] In some cases, HR 472 may drop below the normal HR threshold 478 but remain above the baseline HR 476 because, for example, HR may typically be higher if the patient is standing compared to a sitting HR. Therefore, the normal HR threshold 478 may be greater than the baseline HR but less than the HR change threshold 474, which represents an increase of 477 in HR above the baseline HR 476. For example, the normal HR threshold 478 may be 5 bpm, 10 bpm, 15 bpm, or 20 bpm greater than the baseline HR 472. In other examples, the normal HR threshold 478 may be a specified rate (e.g., 70 bpm to 100 bpm) below which the patient is not expected to experience POTS symptoms.
[0147] Figure 9This is a diagram 500 illustrating the ANS triggering conditions and ANS delivery timeline based on another example. An acceleration (ACC) signal 502, an activity (ACT) metric 512, a heart rate (HR) 522, and an ANS burst 580 are shown. Control circuitry 80 can detect an acceleration signal spike 502 and initiate a post-spike interval 504 to monitor HR and the activity metric, thereby determining whether to trigger treatment delivery circuitry 84 to begin ANS delivery. Control circuitry 80 can determine that the most recent activity metric 512a preceding the detected signal spike 502 is less than a low activity threshold 514 to enable signal spike detection and / or initiate the post-spike interval 504 to detect additional ANS triggering conditions in response to signal spike detection. If the activity metric 512a is greater than the low activity threshold 514, control circuitry 80 can ignore or not enable detection of the signal spike 502 or pause initiating the post-spike interval 504 to monitor HR-related and activity metric-related ANS triggering conditions.
[0148] HR 522 reaches the HR change threshold 524 within the post-peak time interval 504, which represents at least a threshold increase 527 from the baseline HR 526. In this example, the above-described combination is not applied to HR 522. Figure 8 The high heart rate threshold described. However, it should be understood that, in addition to applying the HR change threshold 524, a high heart rate threshold may also be applied to HR 522 to determine whether the HR-related triggering conditions for initiating an ANS are met.
[0149] exist Figure 9 In one example, control circuitry 80 may compare the next activity metric 512b determined after signal spike detection 502 with a low activity threshold 514 or with a second, slightly higher threshold 516 corresponding to the same standing activity level to verify that a detected increase in HR has occurred after acceleration signal spike 502, but without an accompanying increase in body activity. The first activity threshold 514 may be referred to as the "spike detection enable threshold," and the second activity threshold 516 may be referred to as the "ANS trigger condition threshold." The second activity threshold 516 may be greater than the first activity threshold 514. In other examples, the first activity threshold 514 and the second activity threshold 516 are equal.
[0150] In response to the pre-peak activity metric 512a being less than a low activity threshold 514, the detected signal spike 502, the increased heart rate (HR) detected after the detected signal spike 502, and the post-peak activity metric 512b being less than a second activity threshold 516, the treatment delivery circuit 84 initiates an ANS pulse train 580. When a signal spike is detected and subsequently the HR and activity metric meet the ANS triggering condition, the control circuit 80 determines that the ANS triggering condition is met.
[0151] In this example, the ANS pulse train 580 is a continuous pulse train delivered according to the ANS delivery control parameters. As described below, in other examples, the ANS may be delivered as a discontinuous pulse train, for example, where each pulse train is initiated in response to an Asense (or Vsense) signal or a delivered pacing pulse, and is delivered during the atrial refractory period and / or AV junction refractory period. In this example, the ANS pulse train 580 has an initial pulse amplitude 582 and a pulse width 584, as well as a pulse train frequency defined by the pulse period. For clarity, the pulse width 584 of each pulse in the ANS pulse train 580 is scaled and not necessarily relative to... Figure 9 Other signals and events shown are scaled over time. In various examples, the frequency of the pulse train 580 can be 20Hz to 100Hz, 30Hz to 80Hz, or 40Hz to 60Hz.
[0152] In this example, HR 522 begins to decrease during the ANS pulse train 580, but does not drop to the normal HR threshold 528 until the activity metric 512c is determined to meet the increased activity threshold 518. Following a change in body position associated with the signal spike 502, increased physical activity can be observed in the acceleration signal 502 at the onset 506. For example, a patient may begin walking, jogging, running, or engaging in other increased physical activity after sitting or standing up. (See also...) Figure 6 As described, if, after ANS activation, control circuit 80 detects an increase in patient physical activity (e.g., an activity count greater than at least an ADL threshold or a higher physical exertion threshold), control circuit 80 may control treatment delivery circuit 84 to begin terminating ANS pulse train 580.
[0153] like Figure 9 As shown, when the activity metric 512c meets the increased activity threshold 518, the treatment delivery circuit 84 begins to gradually decrease the ANS delivery control parameter (in this case, the pulse amplitude) according to a gradual decrease rate 590. The gradual decrease rate 590 can be correlated with... Figure 8 The step-down rate 490 shown is the same as the rate applied in response to detecting a decrease in HR to the normal HR threshold 478. In other examples, when HR needs to increase to support increased physical activity, the step-down rate 590 applied during ANS in response to the increased activity metric may be a faster rate of decline than the step-down rate 490 applied in response to detecting a decreased HR.
[0154] HR 522 is allowed to increase as the ANS pulse train 580 gradually decreases and can reach a sinus heart rate 532 adapted to the increased activity measure 512c / 512d. In some cases, the increased HR following the increased activity measure 512c may be caused by rate-responsive pacing delivered by the treatment delivery circuit 84 rather than the intrinsic heart rate. If only HR is monitored after initiation of ANS treatment to determine when to terminate ANS treatment, ANS treatment may continue during increased activity, in which case sympathetic tone should increase as parasympathetic tone decreases. Therefore, when rate-responsive pacing is enabled and delivered by the treatment delivery circuit 84, the control circuit 80 can initiate termination of ANS based on the increased activity measure. By terminating the ANS pulse train 580, the intrinsic heart rate can increase to the exercise heart rate 532 required to support the patient's activity level without rate-responsive pacing.
[0155] As long as the activity metric 512 (e.g., activity metrics 512c and 512d) remains above the low activity threshold 514, the control circuit 80 can disable acceleration signal spike detection or ignore any subsequently detected signal spikes. In this way, ANS treatment will not be triggered again due to signal spikes in the acceleration signal 501 until the activity metric 512 drops below the low activity threshold 514.
[0156] Figure 10 This is a diagram 600 illustrating different gradual decrease rates that can be applied to ANS delivery control parameters to gradually terminate ANS treatment in response to the detection of a decreased HR or an increased activity metric during ANS delivery. When an increased activity metric or a decreased HR is detected after the initiation of ANS delivery, the value of the ANS delivery control parameter can be at its maximum (MAX) or initial value. The maximum value here does not necessarily mean the maximum available setting for the ANS delivery control parameter. Rather, the maximum value here refers to the highest value of the ANS delivery control parameter applied during ANS treatment, such as, for example, the highest pulse amplitude, longest pulse width, or highest number of pulses per pulse train delivered according to the programmed ANS delivery control parameter value.
[0157] At time point 602, control circuitry 80 may detect a decrease in HR (e.g., below the normal HR threshold) or an increase in activity metric (e.g., above the increased activity threshold) that necessitates termination of ANS treatment, based on any of the examples described above. The ANS delivery control parameter value (plotted on the y-axis) may be adjusted downwards from its current value (e.g., a maximum of 604) to a minimum of 614. For a given ANS delivery control parameter, the minimum value may be zero, but in some examples it may be non-zero. The minimum value may be such that, below which the ANS pulse train is not expected to have a therapeutic effect of increasing parasympathetic tone.
[0158] The rate of decrease in the ANS delivery control parameter can be proportionally adjusted based on the patient's activity level at time 602. If the most recent activity metric at time 602 indicates a resting activity level, the treatment delivery circuit 84 can cause the ANS delivery control parameter to decrease gradually at the slowest possible rate of decrease 620. The ANS pulse train can be delivered according to the decreasing control parameter value until a minimum value 614 is reached, at which point the ANS treatment is completely terminated (until the next ANS trigger condition is met).
[0159] If the most recently determined activity metric at time point 602 is greater than the ADL threshold, the treatment delivery circuit 84 can cause the ANS delivery control parameter to gradually decrease according to a second, faster rate of decrease 622. In this way, the intrinsic heart rate can be appropriately increased in response to higher levels of non-resting activity.
[0160] If the most recently determined activity measure at time point 602 is greater than the physical exertion threshold level, indicating relatively high physical exertion (greater than ADL), then the treatment delivery circuit 84 can cause the ANS delivery control parameter to gradually decrease according to the third fastest gradual decrease rate 624. In this way, the intrinsic heart rate can be allowed to increase according to the normal physiological response to higher levels of non-resting activity. It should be recognized that in some cases, when the treatment delivery circuit 84 is combined as described above... Figure 9 The described rate response rate can terminate ANS treatment when the atrial or ventricular pacing is delivered.
[0161] Although Figure 10 Three different step-down rates 620, 622 and 624 are shown, but it is conceivable that one, two or more, or more than three step-down rates could be defined for the corresponding activity metric level and / or HR to control how quickly or slowly ANS treatment can be terminated after a decrease in HR and / or an increase in activity level is detected.
[0162] Figure 11 This is a timing diagram 700 of an ANS pulse train 720 that can be delivered by a treatment delivery circuit 84, according to some examples. Atrial EGM signal 702 and ventricular EGM signal 710 can be sensed by sensing circuit 86. Sensing circuit 86 can sense atrial P wave 704 and, for example, transmit an Asense signal 706 to control circuit 80 in response to a P wave sensing threshold exceeding a limit. Sensing circuit 86 can sense R wave 712 and, for example, transmit a Vsense signal 716 to control circuit 80 in response to an R wave sensing threshold exceeding a limit.
[0163] In response to the fulfillment of the ANS treatment triggering condition, the treatment delivery circuit 84 may begin delivering the ANS pulse train 720 according to any of the examples described above. In some examples, each ANS pulse train in the ANS pulse train 720 is initiated in response to a received Asense signal 706. In this way, each ANS pulse train in the ANS pulse train 720 may be delivered at least partially during the atrial refractory period following atrial depolarization.
[0164] The ANS pulse train 720 is delivered according to ANS delivery control parameters to avoid capturing the myocardium. The ANS pulse train 720 is delivered according to the ANS delivery control parameters to increase parasympathetic tone and promote a reduction in the intrinsic atrial rate. The ANS delivery control parameters may include an initial pulse amplitude 722 and an initial pulse width 724. The pulse energy can be increased or decreased as needed by increasing or decreasing the programmed initial pulse amplitude 722 and / or pulse width 724 to promote a therapeutic effect of reducing the atrial rate when an increased heart rate is detected after a detected signal spike.
[0165] As a non-limiting example, the starting pulse amplitude 722 may be between 0.25 volts (V) and 12.0 V, between 1 V and 10 V, or between 4 V and 8 V. As a non-limiting example, the pulse width 724 may be from 0.1 milliseconds (ms) to 10 ms, or about 0.2 ms to 1 ms. The individual pulses of each pulse train in the ANS pulse train 720... Figure 11 The pulses in each pulse train 720 are shown as single-phase pulses. In other examples, the pulses in each pulse train 720 can be multiphase, such as biphase, triphase, etc. The pulses in each pulse train 720 are... Figure 11 The pulse is shown as a positive polarity pulse. In other examples, the pulse can be a negative polarity pulse or a combination of positive and negative polarity pulses, such as alternating positive and negative pulses or n positive pulses followed by n negative pulses, etc. In still some examples, the treatment delivery circuit 84 can control the polarity of the ANS pulse train 252 to alternate, for example, one pulse train can be entirely negative polarity pulses, and the next pulse train can be entirely positive polarity pulses.
[0166] Each pulse within a pulse train is separated from the next pulse by an inter-pulse interval 726. As a non-limiting example, the inter-pulse interval 726 can be from 5 ms to 100 ms. The inter-pulse interval 726 can be selected in conjunction with the pulse width 724 to obtain a desired pulse frequency. The pulse frequency (i.e., the frequency of the pulses within each ANS pulse train in the ANS pulse train 720) is defined by the reciprocal of the pulse period, which is defined by the sum of the pulse width 724 and the inter-pulse interval 726. The pulse frequency can be increased by decreasing the pulse width 724 and / or decreasing the inter-pulse interval 726. In various examples, the pulse frequency can be from 20 Hz to 100 Hz, from 30 Hz to 80 Hz, or from 40 Hz to 60 Hz. For example, to achieve a pulse frequency of approximately 40 Hz to 60 Hz with a pulse width duration of approximately 0.2 ms, the inter-pulse interval can be between approximately 16 ms and 25 ms.
[0167] The pulse train duration 728 is defined by the number of pulses and the pulse period in the pulse train. As an example and not intended to be limiting, the pulse train duration 728 can be from 100 ms to 1 second or between 200 ms and 500 ms. As an example and not a limitation, the pulse train can be from 1 to 20 pulses long or from 3 to 6 pulses long, with a frequency of 10 Hz to 20 Hz. The pulse train duration 728 can be increased by increasing the number of pulses and / or decreasing the pulse frequency. A relatively greater increase in parasympathetic tone can be achieved with an ANS pulse train 720 having relatively high pulse energy, a higher frequency, and / or a longer pulse train duration 728, for the therapeutic benefit of reducing atrial rate and alleviating symptoms associated with POTS. A relatively lower increase in parasympathetic tone can be achieved with relatively low pulse energy, a lower pulse frequency, and / or a shorter pulse train duration 728. Therefore, ANS delivery control parameters can be tuned to achieve a desired parasympathetic response, as demonstrated by a reduced HR. HR reduction can occur faster or slower, depending on the strength (e.g., pulse energy and pulse frequency) and duration of the ANS pulse train.
[0168] As described above, control circuit 80 can detect ANS termination conditions. As an example, an ANS termination condition could be an increased activity metric during ANS delivery, a decreased heart rate (HR) during ANS delivery, or a maximum ANS delivery timeout. Treatment delivery circuit 84 can initiate a gradual descent process in response to the ANS termination condition to gradually terminate ANS treatment.
[0169] In the example shown, control circuitry 80 can detect a decrease in HR in response to PPI 732 (between consecutive Asense signals 706) meeting the normal HR threshold interval. In other examples, control circuitry 80 can detect a decrease in HR in response to PPI 732 being longer than the previous PPI 730. Although Figure 11 For illustrative purposes, a single, longer PPI 732 is shown, but it should be understood from the example given above that the control circuit 80 can detect a reduced HR based on the analysis of multiple sensed cardiac event intervals.
[0170] In response to the detection of a decreased heart rate (HR), the treatment delivery circuit 84 can deliver the next ANS pulse train 740 with a lower pulse energy. The pulse energy can be gradually reduced by decreasing the pulse amplitude and / or pulse width over consecutive ANS pulse trains. In this example, the pulse amplitude 736 is reduced from the initial pulse amplitude 722, where the pulse width, pulse frequency, and pulse train duration remain the same. In other examples, one or more of the pulse amplitude, pulse width, pulse frequency, and / or pulse train duration can be gradually reduced over one or more ANS pulse trains to an end value or minimum value, at which point ANS treatment is completely terminated. It should be understood that the pulse frequency may not be reduced, or may be reduced to a minimum frequency (e.g., not less than 20 Hz) to avoid capturing myocardial tissue.
[0171] In this example, the ANS pulse train 720 is delivered during the atrial refractory period and may extend beyond the atrial refractory period after each Asense signal 706, or may not extend beyond it. In some examples, the pulse train duration 720 may extend into at least a portion of the ventricular refractory period. In other examples, the ANS pulse train terminates before the Vsense signal to avoid any excessive prolongation of AV node conduction. In still other examples, the ANS pulse train may be triggered on each Vsense signal 716, rather than by each Asense signal in Asense signal 706 as shown. When Asense signal 706 or Vsense signal 716 is used by control circuitry 80 as a trigger to initiate the ANS pulse train, the pulse train duration may be defined as being as long as or shorter than the atrial refractory period, or as long as or shorter than the ventricular refractory period. For example, Asense signal 706 may be used to trigger each ANS pulse train unless atrial fibrillation or an atrial rate faster than a threshold rapid atrial rate is detected. In this configuration, the Vsense signal 716 can be used by the control circuit 80 to trigger the ANS pulse train. In further examples, the ANS pulse train can be triggered by both the Asense and Vsense signals and delivered during the respective atrial and ventricular refractory periods. It is conceivable that when the IMD is configured to detect ventricular tachyarrhythmias, the ANS could be suppressed or terminated if ventricular tachycardia or ventricular fibrillation is detected.
[0172] Figure 12 This is a flowchart 800 of a method for controlling ANS treatment performed by a medical device system according to some examples. At block 802, control circuitry 80 receives a sensed cardiac event signal from sensing circuitry 86 and an acceleration signal from sensor circuitry 92 for detecting when an ANS treatment trigger condition is met, according to any of the examples described above. At block 804, control circuitry 80 determines that an ANS treatment trigger condition is met when at least an acceleration signal spike is detected. As described above, an ANS treatment trigger condition is determined to be met when an acceleration signal spike is detected and an increased heart rate (HR) is detected during the time interval following the spike, while the activity metric does not increase.
[0173] ANS treatment will not be delivered as long as the ANS triggering condition is not met. In some examples, the medical device system may receive a POTS confirmation signal entered by the patient or another caregiver via an external device, such as in combination with... Figure 1As described. In some examples, a patient may be able to trigger ANS treatment by using external device 50 to override the ANS triggering condition requirements. In other examples, when IMD 14 receives a POTS confirmation signal from external device 50, control circuitry 80 may determine at block 808 whether a secondary ANS triggering condition is met.
[0174] In some examples, if a POTS acknowledgment signal is received and at least one other ANS treatment trigger condition is met, control circuitry 80 may determine at block 808 that a secondary ANS trigger condition is met. For example, if an acceleration signal spike is detected and a POTS acknowledgment signal is received, control circuitry 80 may trigger ANS treatment delivery by treatment delivery circuitry 84 at block 814 even if other ANS trigger conditions related to HR and activity are not met. In other examples, if a POTS acknowledgment signal is received and an increase in the threshold HR is detected, control circuitry 80 may trigger ANS treatment delivery at block 814. In yet another example, if a POTS acknowledgment signal is received at block 806 and a signal spike is detected but ignored because the pre-spike activity metric is greater than the low activity threshold, control circuitry 80 may trigger ANS treatment delivery at block 814. If the secondary ANS trigger condition is not met at block 808, control circuitry 80 may proceed to block 810.
[0175] In response to receiving a POTS confirmation signal from an external device at block 806, acceleration signal data and / or HR data corresponding to the confirmed POTS episode can be recorded in the medical device system memory at block 810. In some examples, external device 50 may send an interrogation signal to IMD 14 to request data to be sent from IMD 14. In other examples, external device 50 may send a POTS confirmation signal to IMD 14 at block 806, such that IMD 14 may record the acceleration signal and / or HR data as an untreated POTS episode in memory 82 at block 810.
[0176] Control circuit 80 may buffer the most recent segment of the acceleration signal used for signal spike detection in memory 82, making the segment of acceleration signal available for analysis when a POTS acknowledgment signal is received. In some cases, a signal spike may be detected, but other ANS trigger conditions are not met. In other examples, a signal spike may not be detected, thus preventing the ANS trigger conditions from being met. If a signal spike is not detected, control circuit 80 may adjust one or more thresholds or ranges stored in memory 82 as body position change motion criteria for detecting acceleration signal spikes. For example, the conversion rate threshold or magnitude change threshold applied to the acceleration signal may be lowered, so that a signal spike present in the buffered acceleration signal segment will now be detected.
[0177] In addition to buffering acceleration signal segments, or as an alternative, control circuitry 80 may buffer HR data and / or activity metrics in memory 82, which may be recorded in response to receiving a POTS confirmation signal. When a signal spike is detected but the HR-related and / or activity-related ANS treatment trigger conditions are not met, but a POTS confirmation signal is received, control circuitry 80 may analyze the HR data and / or activity metrics to adjust one or more thresholds or other criteria applied by control circuitry 80 for detecting ANS treatment trigger conditions.
[0178] In some cases, when a POTS confirmation signal is received, the patient's activity level may be higher than the low activity threshold at the time when the signal spike is not detected or ignored. In such cases, the low activity threshold (e.g., see...) Figure 8 The low activity threshold 464 in the signal can be increased by the control circuit 80, so that signal spike detection can be enabled at relatively high patient activity levels.
[0179] In other examples, HR-related triggering conditions can be adjusted. For instance, the increased HR threshold 474 can be reduced based on HR changes determined from recorded data associated with untreated POTS episodes (e.g., by adjusting data from...). Figure 8 The baseline HR reduction threshold shown is increased by 476. Additionally or alternatively, in some examples, the high heart rate threshold may be reduced by 475 (…). Figure 8 (as shown in the diagram), or the requirement can be removed from the ANS treatment trigger conditions. Generally, if recorded data associated with one or more confirmed but untreated POTS episodes indicates that POTS occurs when the increase in HR is small and / or at a lower HR than required by the HR-related trigger condition, the HR-related trigger condition can be adjusted by the control circuit 80.
[0180] In some other examples, at box 812, the activity-related triggering condition can be adjusted based on the recorded activity measure associated with the confirmed POTS episode. As described above, the pre-peak low activity threshold can be increased. Additionally or alternatively, if the patient activity measure associated with the confirmed POTS episode is higher than the current post-peak ANS triggering condition threshold, thereby preventing the delivery of ANS treatment, the post-peak ANS triggering condition threshold can be increased (e.g., Figure 9 The second activity threshold 516 shown is used to enable the ANS treatment triggering condition to be met.
[0181] In some examples, multiple POTS confirmation signals may be received, allowing any adjustment to the ANS trigger condition detection control parameters performed at block 812 to be based on data recorded for multiple POTS seizures. Furthermore, although in flowchart 800, the adjustment of the ANS trigger condition detection parameters at block 812 is shown to occur after the ANS trigger condition is not met, it is conceivable that ANS trigger condition data may be recorded upon triggering ANS treatment and / or upon receiving a POTS confirmation signal. In this way, control circuitry 80 can determine when activity metrics, heart rate (HR), and / or signal spike characteristics just meet the ANS trigger condition, such that the ANS trigger condition is not met in some cases but is met in others. Control circuitry 80 can identify one or more ANS trigger condition detection control parameters that, if adjusted, increase the likelihood of triggering ANS treatment for POTS seizures that have been confirmed by a user-input signal but have not been treated with ANS treatment.
[0182] Furthermore, it is conceivable that the data recorded at box 810 (with or without attack data recorded in memory 82 when ANS treatment trigger conditions are met) can be presented to clinicians or other users by external device 50. In some examples, clinicians can view confirmed POTS attack data to manually adjust the ANS treatment trigger condition detection control parameters programmed into IMD 14, thereby increasing the likelihood of delivering ANS treatment when the patient is likely to experience POTS.
[0183] This document also discloses the subject matter of the following embodiments: Example 1. A medical device system comprising: a sensor circuit configured to sense an acceleration signal; a cardiac signal sensing circuit configured to sense a cardiac signal; and a memory configured to store a postural change criterion. The medical device system further comprises a control circuit configured to: detect a signal spike from the acceleration signal that satisfies the postural change criterion; detect a first heart rate from the cardiac signal sensed by the cardiac signal sensing circuit after the detection of the signal spike; and detect an increased heart rate based on the first heart rate. The medical device system further comprises a treatment delivery circuit configured to deliver autonomic nerve stimulation (ANS) to reduce the first heart rate in response to the control circuit detecting the spike and the increased heart rate.
[0184] Example 2. The medical device system according to Example 1, wherein the control circuit is further configured to: determine a pre-peak patient physical activity measure from the acceleration signal sensed by the sensor circuit prior to the detected postural signal peak; and determine that the pre-peak patient physical activity measure is less than a low activity threshold. The treatment delivery circuit is further configured to deliver the ANS to reduce the first heart rate in response to the control circuit detecting the signal peak, detecting the increased heart rate, and determining that the pre-peak patient activity level is less than the activity threshold.
[0185] Example 3. A medical device system according to any one of Examples 1 to 2, wherein the sensor circuit is further configured to sense a patient activity signal. The control circuit is further configured to: determine a post-peak patient physical activity metric from the patient activity signal sensed by the sensor circuit after the signal spike is detected; and determine that the post-peak patient physical activity metric is less than an increased activity threshold. The treatment delivery circuit is further configured to deliver the ANS to reduce the first heart rate in response to the control circuit determining that the post-peak patient physical activity metric is less than the increased activity threshold after the signal spike is detected and detecting the increased heart rate.
[0186] Example 4. A medical device system according to any one of Examples 1 to 3, wherein the control circuit is further configured to: determine a baseline heart rate from the heart signal sensed by the heart signal sensing circuit; and determine a heart rate change as the difference between the baseline heart rate and the first heart rate. The control circuit can detect the increased heart rate by: determining that the heart rate change satisfies a threshold increase; and determining that the first heart rate is greater than a high heart rate threshold.
[0187] Example 5. A medical device system according to any one of Examples 1 to 4, wherein the cardiac signal sensing circuit is configured to sense the cardiac signal by sensing an atrial signal. The control circuit is further configured to detect the increased heart rate by: determining a baseline atrial rate from the atrial signal sensed within a first time interval of the detected signal spike; determining the first heart rate from the atrial signal; determining the atrial rate difference between the baseline atrial rate and the first heart rate; and detecting the increased heart rate by at least determining that the atrial rate difference is greater than a threshold increase.
[0188] Example 6. A medical device system according to any one of Examples 1 to 5, wherein the sensor circuit is further configured to sense a patient activity signal. The control circuit is further configured to: determine a patient physical activity measure from the patient activity signal sensed by the sensor circuit after the treatment delivery circuit begins delivery of the ANS; and detect increased patient physical activity based on the patient physical activity measure determined after the treatment delivery circuit begins delivery of the ANS. The treatment delivery circuit is further configured to terminate the ANS in response to the control circuit detecting the increased patient physical activity.
[0189] Example 7. A medical device system according to any one of Examples 1 to 6, wherein the control circuit is further configured to: determine a second heart rate from the heart signal sensed by the heart signal sensing circuit after the treatment delivery circuit begins delivery of the ANS; and determine that the second heart rate is less than the first heart rate. The treatment delivery circuit is further configured to terminate the ANS in response to the control circuit determining that the second heart rate is less than the first heart rate.
[0190] Example 8. A medical device system according to any one of Examples 1 to 7, wherein the treatment delivery circuit is further configured to: deliver the ANS according to treatment delivery control parameters; and terminate the ANS by gradually decreasing the treatment delivery control parameters.
[0191] Example 9. A medical device system according to any one of Examples 1 to 8, wherein the sensor circuit is further configured to sense a patient activity signal. The control circuit is further configured to: detect increased patient physical activity from the patient activity signal sensed by the sensor circuit after the treatment delivery circuit begins delivery of the ANS; and determine a gradual decrease rate based on the detected increased patient physical activity. The treatment delivery circuit is further configured to: deliver the ANS according to treatment delivery control parameters; and terminate the ANS by gradually decreasing the treatment delivery control parameters according to the gradual decrease rate determined by the control circuit.
[0192] Example 10. A medical device system according to any one of Examples 1 to 9, wherein the control circuit is further configured to: receive a patient confirmation signal confirming an attack of postural orthostatic tachycardia syndrome; and, in response to receiving the patient confirmation signal, buffer data determined from the acceleration signal and the cardiac signal in the memory.
[0193] Example 11. The medical device system according to Example 10, wherein the control circuit is further configured to: adjust the ANS trigger condition detection control parameters in response to receiving the patient confirmation signal; and detect an ANS trigger condition in response to at least one of the acceleration signal or the cardiac signal satisfying the adjusted ANS trigger condition detection control parameters. The treatment delivery circuit is further configured to deliver the ANS in response to the control circuit detecting the ANS trigger condition.
[0194] Example 12. The medical device system according to Example 11, wherein the control circuit is further configured to adjust the ANS trigger condition detection control parameter by adjusting at least one of the following: a pre-peak low activity threshold; a signal peak detection threshold; a post-peak activity threshold; an increased heart rate threshold; or a high heart rate threshold.
[0195] Example 13. A medical device system according to any one of Examples 10 to 12, the medical device system further includes an external device having a display unit and a user interface for receiving the patient confirmation signal. The medical device system includes an implantable medical device including the sensor circuitry, the cardiac signal sensing circuitry, the memory, the control circuitry, and the treatment delivery circuitry. The implantable medical device also includes telemetry circuitry for transmitting buffered data. The external device is configured to display the buffered data via the display unit.
[0196] Example 14. A medical device system according to any one of Examples 1 to 13, wherein the control circuit is further configured to: determine a second heart rate from a heart signal sensed by the heart signal sensing circuit after the treatment delivery circuit begins delivering the ANS; determine that the second heart rate is not lower than the first heart rate; and adjust the ANS delivery control parameters in response to determining that the second heart rate is not lower than the first heart rate. The treatment delivery circuit is further configured to deliver the ANS according to the adjusted ANS delivery control parameters.
[0197] Example 15. The medical device system also includes electrodes coupled to the treatment delivery circuit for delivering the ANS to the treatment delivery site to increase parasympathetic tone.
[0198] Example 16. A medical device system according to any one of Examples 1 to 15, wherein the treatment delivery circuit is further configured to deliver the ANS by delivering a continuous pulse train.
[0199] Example 17. A medical device system according to any one of Examples 1 to 16, wherein the cardiac signal sensing circuit is further configured to sense a cardiac event signal from the cardiac signal by sensing at least one of an atrial P wave or a ventricular R wave from the cardiac signal. The treatment delivery circuit is further configured to deliver the ANS by delivering a plurality of discontinuous pulse trains, wherein each pulse train is triggered in response to one of an atrial P wave sensed by the cardiac signal sensing circuit or a ventricular R wave sensed by the sensing circuit.
[0200] Example 18. A method comprising: sensing an acceleration signal; sensing a cardiac signal; storing a postural change criterion in a medical device memory; and detecting a signal spike from the acceleration signal that satisfies the postural change criterion. The method further comprises: detecting a first heart rate from the cardiac signal sensed after detecting the signal spike; detecting an increased heart rate based on the first heart rate; and, in response to detecting the spike and the increased heart rate, delivering an autonomic nerve stimulation (ANS) to reduce the first heart rate.
[0201] Example 19. The method according to Example 18, further comprising: determining a pre-peak patient physical activity metric from the acceleration signal sensed prior to the detected postural signal spike; determining that the pre-peak patient physical activity metric is less than a low activity threshold. In response to detecting the signal spike, detecting the increased heart rate, and determining that the pre-peak patient activity level is less than the activity threshold, the ANS is delivered to reduce the first heart rate.
[0202] Example 20. The method according to any one of Examples 18 to 19, further comprising: sensing a patient activity signal; determining a post-peak patient physical activity metric from the patient activity signal sensed after the signal peak is detected; and determining that the post-peak patient physical activity metric is less than an increased activity threshold. In response to determining that the post-peak patient physical activity metric is less than the increased activity threshold after the signal peak is detected and detecting the increased heart rate, the ANS is delivered to reduce the first heart rate.
[0203] Example 21. The method according to any one of Examples 19 to 20, further comprising: determining a baseline heart rate from the cardiac signal; determining a heart rate change as the difference between the baseline heart rate and the first heart rate; and detecting the increased heart rate by: determining that the heart rate change satisfies a threshold increase; and determining that the first heart rate is greater than a high heart rate threshold.
[0204] Example 22. The method according to any one of Examples 18 to 21, further comprising: sensing the cardiac signal by sensing the atrial signal; and detecting the increased heart rate by: determining a baseline atrial rate from the atrial signal sensed within a first time interval of the detected signal peak; determining the first heart rate from the atrial signal; determining an atrial rate difference between the baseline atrial rate and the first heart rate; and detecting the increased heart rate by at least determining that the atrial rate difference is greater than a threshold increase.
[0205] Example 23. The method according to any one of Examples 18 to 22, further comprising: sensing a patient activity signal; determining a patient physical activity metric from the patient activity signal sensed after the start of the ANS; and detecting increased patient physical activity based on the patient physical activity metric determined after the start of ANS delivery. The method further comprises terminating the ANS in response to detecting the increased patient physical activity.
[0206] Example 24. The method according to any one of Examples 18 to 23, further comprising: detecting a second heart rate less than the first heart rate from the cardiac signal sensed after the start of the ANS delivery; and terminating the ANS in response to detecting the second heart rate less than the first heart rate.
[0207] Example 25. The method according to any one of Examples 18 to 24, further comprising: delivering the ANS according to a treatment delivery control parameter; and terminating the ANS by gradually decreasing the treatment delivery control parameter.
[0208] Example 26. The method according to any one of Examples 18 to 25, further comprising: sensing a patient activity signal; detecting increased patient physical activity from the patient activity signal sensed after the start of ANS delivery; and determining a gradual decrease rate based on the detected increased patient physical activity. The method further comprises: delivering the ANS according to a treatment delivery control parameter; and terminating the ANS by gradually decreasing the treatment delivery control parameter according to the determined gradual decrease rate.
[0209] Example 27. The method according to any one of Examples 18 to 26, further comprising: receiving a patient confirmation signal confirming an attack of postural orthostatic tachycardia syndrome; and buffering data determined from the acceleration signal and the cardiac signal in response to receiving the patient confirmation signal.
[0210] Example 28. The method according to Example 27, further comprising adjusting ANS trigger condition detection control parameters in response to receiving the patient confirmation signal. The method further comprises: detecting an ANS trigger condition in response to at least one of the acceleration signal or the cardiac signal satisfying the adjusted ANS trigger condition detection control parameters; and delivering the ANS in response to detecting the ANS trigger condition.
[0211] Example 29. According to the method of Example 28, adjusting the ANS trigger condition detection control parameter includes adjusting at least one of the following: a pre-peak low activity threshold; a signal peak detection threshold; a post-peak activity threshold; an increased heart rate threshold; or a high heart rate threshold.
[0212] Example 30. The method according to any one of Examples 27 to 29, further comprising: receiving the patient confirmation signal via an external device having a display unit and a user interface; transmitting the buffered data from the implantable medical device to the external device; and displaying the buffered data by the display unit.
[0213] Example 31. The method according to any one of Examples 18 to 30, further comprising: determining a second heart rate from the cardiac signal sensed after the start of ANS delivery; determining that the second heart rate is not lower than the first heart rate; adjusting ANS delivery control parameters in response to determining that the second heart rate is not lower than the first heart rate; and delivering the ANS according to the adjusted ANS delivery control parameters.
[0214] Example 32. The method also includes delivering the ANS to the treatment delivery site to increase parasympathetic tone.
[0215] Example 33. The method according to any one of Examples 18 to 32, further comprising delivering the ANS by delivering a continuous pulse train.
[0216] Example 34. The method according to any one of Examples 18 to 32, further comprising: sensing a cardiac event signal from the cardiac signal by sensing at least one of an atrial P wave or a ventricular R wave from the cardiac signal; and delivering the ANS by delivering a plurality of discontinuous pulse trains, wherein each pulse train is triggered in response to a sensed atrial P wave or a sensed ventricular R wave from the cardiac signal.
[0217] Example 35. A non-transitory computer-readable medium storing a postural change exercise criterion and a set of instructions, which, when executed by control circuitry of a medical device system, cause the medical device system to: sense an acceleration signal; sense a cardiac signal and store it in a medical device memory; detect a signal spike from the acceleration signal that satisfies the postural change exercise criterion; detect a first heart rate from the cardiac signal sensed after the detection of the signal spike; and detect an increased heart rate based on the first heart rate. The instructions also cause the medical device system to deliver autonomic nerve stimulation (ANS) in response to the detection of the spike and the increased heart rate to reduce the first heart rate.
[0218] It should be understood that, depending on the example, certain actions or events in any of the methods described herein may be performed in a different order, and may be added, combined, or omitted entirely (e.g., not all described actions or events are necessary for practicing the method). Furthermore, in some examples, actions or events may be performed simultaneously, for example, through multithreading, interrupt handling, or multiple processors, rather than sequentially. In addition, for clarity, although some aspects of this disclosure are described as being performed by a single circuit or unit, it should be understood that the techniques of this disclosure may be performed by a combination of units or circuits associated with, for example, a medical device.
[0219] In one or more examples, the described functionality may be implemented in hardware, software, firmware, or any combination thereof. If implemented in software, the functionality may be stored as one or more instructions or code on a computer-readable medium and executed by a hardware-based processing unit. A computer-readable medium may include a computer-readable storage medium, which corresponds to a tangible medium such as a data storage medium (e.g., RAM, ROM, EEPROM, flash memory, or any other medium that can be used to store desired program code in the form of instructions or data structures and is accessible by a computer).
[0220] Instructions can be executed by one or more processors (such as one or more digital signal processors (DSPs)), general-purpose microprocessors, application-specific integrated circuits (ASICs), field-programmable logic arrays (FPLAs), or other equivalent integrated or discrete logic circuits. Therefore, as used herein, the term "processor" can refer to any of the foregoing structures or any other structure suitable for implementing the techniques described herein. Furthermore, these techniques can be fully implemented in one or more circuit or logic elements.
[0221] Therefore, a medical device has been presented in the foregoing description with reference to specific embodiments. It should be understood that the various aspects disclosed herein can be combined with combinations different from the specific combinations presented in the drawings. It should be understood that various modifications can be made to the reference examples without departing from the scope of this disclosure and the following claims.
Claims
1. A medical device system, the medical device system comprising: A sensor circuit configured to sense acceleration signals; A cardiac signal sensing circuit, the cardiac signal sensing circuit being configured to sense cardiac signals; A memory configured to store motion criteria for changes in body position; Control circuit, the control circuit being configured to: Detect signal spikes from the acceleration signal that satisfy the postural change motion criteria; A first heart rate is detected from the heart signal sensed by the heart signal sensing circuit after the signal spike is detected; as well as The increased heart rate is detected based on the first heart rate; and A treatment delivery circuit configured to deliver autonomic nerve stimulation (ANS) to reduce the first heart rate in response to the control circuit detecting the spike and the increased heart rate.
2. The medical device system according to claim 1, wherein: The control circuit is also configured to: Determine the patient's pre-peak body activity measure from the acceleration signal sensed by the sensor circuit prior to the detected postural signal peak; and It was determined that the patient's physical activity measure before the spike was less than the low activity threshold; and The treatment delivery circuit is also configured to deliver the ANS to reduce the first heart rate in response to the control circuit detecting the signal spike, detecting the increased heart rate, and determining that the patient's activity level before the spike is less than the activity threshold.
3. The medical device system according to any one of claims 1 to 2, wherein: The sensor circuit is also configured to sense patient activity signals; The control circuit is also configured to: Determine the patient's physical activity measure after the spike from the patient activity signal sensed by the sensor circuit after the spike is detected; as well as After the spike, the patient's physical activity metric was determined to be less than the increased activity threshold; and The treatment delivery circuit is also configured to deliver the ANS to reduce the first heart rate in response to the control circuit determining that the patient's post-peak physical activity measure is less than the increased activity threshold after the signal spike is detected and the increased heart rate is detected.
4. The medical device system according to any one of claims 1 to 3, wherein the control circuit is further configured to: Determine the baseline heart rate from the heart signals sensed by the heart signal sensing circuit; The heart rate change is defined as the difference between the baseline heart rate and the first heart rate; as well as The increased heart rate is detected by the following steps: Determine that the heart rate change satisfies a threshold increase; and It is determined that the first heart rate is greater than the high heart rate threshold.
5. The medical device system according to any one of claims 1 to 4, wherein: The sensor circuit is also configured to sense patient activity signals; The control circuit is also configured to: The patient's physical activity measure is determined from the patient activity signal sensed by the sensor circuit after the ANS is delivered by the treatment delivery circuit; as well as Increased patient physical activity is detected based on the patient's physical activity metric determined after the treatment delivery circuit begins delivering the ANS; and The treatment delivery circuit is also configured to terminate the ANS in response to the control circuit detecting the increased patient physical activity.
6. The medical device system according to any one of claims 1 to 5, wherein: The control circuit is also configured to: A second heart rate is detected from the heart signal sensed by the heart signal sensing circuit after the ANS is delivered by the treatment delivery circuit; and It is determined that the second heart rate is less than the first heart rate; and The treatment delivery circuit is also configured to terminate the ANS in response to the control circuit determining that the second heart rate is less than the first heart rate.
7. The medical device system according to any one of claims 1 to 6, wherein the treatment delivery circuit is further configured to: The ANS is delivered according to treatment delivery control parameters; and The ANS is terminated by gradually decreasing the treatment delivery control parameters.
8. The medical device system according to any one of claims 1 to 7, wherein: The sensor circuit is also configured to sense patient activity signals; The control circuit is also configured to: Increased patient physical activity is detected from the patient activity signals sensed by the sensor circuit after the ANS is delivered by the treatment delivery circuit; and The rate of gradual decline was determined based on the detected increase in patient physical activity; and The treatment delivery circuit is also configured to: The ANS is delivered according to the treatment delivery control parameters; as well as The ANS is terminated by gradually decreasing the treatment delivery control parameter according to the gradual decreasing rate determined by the control circuit.
9. The medical device system according to any one of claims 1 to 8, wherein the control circuit is further configured to: Receive confirmation signals from patients experiencing a confirmed episode of postural orthostatic tachycardia syndrome; and In response to receiving the patient confirmation signal, data determined from the acceleration signal and the cardiac signal is buffered in the memory.
10. The medical device system according to any one of claims 1 to 9, wherein: The control circuit is also configured to: A second heart rate is determined from the heart signals sensed by the heart signal sensing circuit after the ANS is delivered by the treatment delivery circuit. It was determined that the second heart rate was not lower than the first heart rate; as well as In response to determining that the second heart rate has not decreased compared to the first heart rate, the ANS delivery control parameters are adjusted; and The treatment delivery circuit is also configured to deliver the ANS according to adjusted ANS delivery control parameters.
11. The medical device system according to any one of claims 1 to 10, the medical device system further comprising an electrode coupled to the treatment delivery circuit for delivering the ANS to the treatment delivery site to increase parasympathetic tone.
12. The medical device system according to any one of claims 1 to 11, wherein the treatment delivery circuit is further configured to deliver the ANS by delivering a continuous pulse train.
13. The medical device system according to any one of claims 1 to 12, wherein: The cardiac signal sensing circuit is further configured to sense a cardiac event signal from the cardiac signal by sensing at least one of an atrial P wave or a ventricular R wave from the cardiac signal; and The treatment delivery circuit is also configured to deliver the ANS by delivering a plurality of discontinuous pulse trains, wherein each pulse train is triggered in response to either an atrial P wave sensed by the cardiac signal sensing circuit or a ventricular R wave sensed by the sensing circuit.
14. A method, the method comprising: Sensing acceleration signals; Detecting heart signals; The movement standards for changing body position are stored in the medical device's memory; Detect signal spikes from the acceleration signal that satisfy the postural change motion criteria; The first heart rate is detected from the heart signal sensed after the signal spike is detected; The increased heart rate is detected based on the first heart rate; as well as In response to the detection of the spike and the increased heart rate, autonomic nerve stimulation (ANS) is delivered to reduce the first heart rate.
15. The method according to claim 14, further comprising: Determine the patient's physical activity measure prior to the peak from the acceleration signal sensed prior to the detected postural signal peak; It was determined that the patient's physical activity measure before the peak was less than the low activity threshold; as well as In response to the detection of the signal spike, the detection of the increased heart rate, and the determination that the patient's activity level prior to the spike is less than the activity threshold, the ANS is delivered to reduce the first heart rate.
Citation Information
Patent Citations
Implantable medical device and method for determining His bundle pacing capture
US11007369B2
Electrodes for intra-cardiac pacemaker
US11426578B2
Atrioventricular nodal stimulation
US20210228892A1
Accelerometer count calculation for activity signal for an implantable medical device
US6449508B1
